

## ORIGINAL ARTICLE

# Guidelines for seizure management in palliative care: proposal for an updated clinical practice model based on a systematic literature review<sup>☆</sup>



M. León Ruiz<sup>a,\*</sup>, M.L. Rodríguez Sarasa<sup>b</sup>, L. Sanjuán Rodríguez<sup>c</sup>, M.T. Pérez Nieves<sup>b,d</sup>, F. Ibáñez Estélez<sup>e</sup>, S. Arce Arce<sup>f,g</sup>, E. García-Albea Ristol<sup>h,i</sup>, J. Benito-León<sup>j,k,l</sup>

<sup>a</sup> Servicio de Neurología, Clínica San Vicente, Madrid, Spain

<sup>b</sup> Departamento de Gerencia, Clínica San Vicente, Madrid, Spain

<sup>c</sup> Departamento de Dirección de Gestión Sanitaria, Clínica San Vicente, Madrid, Spain

<sup>d</sup> Servicio de Rehabilitación y Medicina Física, Clínica San Vicente, Madrid, Spain

<sup>e</sup> Servicio de Medicina Interna, Clínica San Vicente, Madrid, Spain

<sup>f</sup> Servicio de Psiquiatría, Clínica San Vicente, Madrid, Spain

<sup>g</sup> Departamento de Dirección Médica, Clínica San Vicente, Madrid, Spain

<sup>h</sup> Servicio de Neurología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

<sup>i</sup> Departamento de Medicina, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

<sup>j</sup> Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>k</sup> Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

<sup>l</sup> Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

Received 25 June 2016; accepted 24 November 2016

Available online 2 November 2018

### KEYWORDS

Cancer;  
Epileptic seizure;  
Palliative care;  
Epilepsy;  
Antiepileptic drug;  
Terminal illness

### Abstract

**Introduction:** Very little has been written on seizure management in palliative care (PC). Given this situation, and considering the forthcoming setting up of the Palliative Care Unit at our neurorehabilitation centre, the Clínica San Vicente, we decided to establish a series of guidelines on the use of antiepileptic drugs (AEDs) for handling seizures in PC.

**Methods:** We conducted a literature search in PubMed to identify articles, recent manuals, and clinical practice guidelines on seizure management in PC published by the most relevant scientific societies.

**Results:** Clinical practice guidelines are essential to identify patients eligible for PC, manage seizures adequately, and avoid unnecessary distress to these patients and their families. Given the profile of these patients, we recommend choosing AEDs with a low interaction potential and which can be administered by the parenteral route, preferably intravenously. Diazepam and midazolam appear to be the most suitable AEDs during the acute phase whereas levetiracetam, valproic acid, and lacosamide are recommended for refractory cases and long-term treatment.

<sup>☆</sup> Please cite this article as: León Ruiz M, Rodríguez Sarasa ML, Sanjuán Rodríguez L, Pérez Nieves MT, Ibáñez Estélez F, Arce Arce S, et al. Guía para el manejo de las crisis epilépticas en cuidados paliativos: propuesta de un modelo actualizado de práctica clínica basado en una revisión sistemática de la literatura. Neurología. 2019;34:165–197.

\* Corresponding author.

E-mail address: [pistolpete271285@hotmail.com](mailto:pistolpete271285@hotmail.com) (M. León Ruiz).

**PALABRAS CLAVE**

Cáncer;  
Crisis epiléptica;  
Cuidados paliativos;  
Epilepsia;  
Fármaco  
antiepiléptico;  
Situación de  
enfermedad terminal

**Conclusions:** These guidelines provide general recommendations that must be adapted to each particular clinical case. Nevertheless, we will require further well-designed randomised controlled clinical trials including large samples of patients eligible for PC to draft a consensus document recommending adequate, rational, and effective use of AEDs, based on a high level of evidence, in this highly complex area of medical care.

© 2017 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### Guía para el manejo de las crisis epilépticas en cuidados paliativos: propuesta de un modelo actualizado de práctica clínica basado en una revisión sistemática de la literatura

**Resumen**

**Introducción:** Dada la escasez de directrices abordando este tema y con motivo de la futura creación de la Unidad de Cuidados Paliativos (CP) en nuestro centro de neurorrehabilitación, los miembros del equipo médico de la Clínica San Vicente hemos decidido proponer una serie de sugerencias sobre el empleo de fármacos antiepilépticos (FAEs) en el manejo de las crisis epilépticas (CEs) en CP.

**Métodos:** Búsqueda de artículos en PubMed, últimos libros y recomendaciones de las guías de práctica clínica y sociedades científicas publicadas más relevantes, referentes al manejo de las CEs en CP.

**Resultados:** La confección de este tipo de guías, además de identificar pacientes candidatos a recibir CP, es fundamental para garantizar un buen control sintomático de las CEs y evitar el sufrimiento innecesario de estos enfermos y sus familiares. Dadas las características de estos pacientes, se recomienda usar FAEs con presentación vía parenteral (preferiblemente intravenosa) y un perfil bajo de interacciones. Diazepam y/o midazolam serían los más idóneos para la fase aguda, y levetiracetam, ácido valproico y/o lacosamida para casos refractarios y/o como tratamiento crónico.

**Conclusiones:** Estas recomendaciones deben considerarse una guía de abordaje integral, debiendo adaptarse a la idiosincrasia de cada caso clínico en particular. Sin embargo, se necesitan ensayos clínicos controlados, aleatorizados, bien diseñados, que incluyan muestras amplias de pacientes subsidiarios de CP, para redactar un documento de consenso que permita recomendar con un mayor nivel de evidencia y de forma generalizada, la utilización adecuada, racional y efectiva de FAEs en este ámbito médico-asistencial de elevada complejidad.

© 2017 El Autor(s). Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Neurología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

Population ageing and the increasing prevalence of cancer and chronic degenerative diseases constitute a significant challenge for health services. At the end of their lives, many of these patients are severely sick and require care involving all levels of the health service. Between 50% and 60% of people who die in Spain are estimated to have experienced a process of deterioration in the final year of life. Patients in this period of life are thought to account for 8% to 22% of hospital admissions.<sup>1-3</sup> There is also a societal demand for quality, cost-effective, person-centred care enabling patients to live and die with dignity. The above underscores the need to reconsider the aims of today's medicine, which so far has excessively emphasised curative care. In his 2000 article in the prestigious *New England Journal of Medicine*, Callaghan<sup>4</sup> argued for the recognition of a peaceful death as an objective of equal value and importance as prolonging

life and fighting disease. The neurological deficits observed in patients with brain tumours may result from the primary effects of cancer, systemic complications, or from adverse reactions to oncological treatment. In the first stages of the neoplastic process, neurorehabilitation generally aims to restore patients' cognitive function following cancer treatment, whereas at later stages it focuses on maintaining their autonomy and quality of life. Neurorehabilitation has been shown to be beneficial, especially in the acute phase of oncological disease, with functional gains comparable to those achieved by other models designed for such other neurological diseases as stroke or traumatic brain injury. Despite this evidence, neurorehabilitation is underused in treating these patients.<sup>5</sup> The overall view of palliative care (PC) is that such treatment may be beneficial for patients with irreversible, progressive, non-cancer diseases with a terminal phase, such as advanced-stage chronic obstructive pulmonary disease; heart, liver, or kidney failure; and

such neurological diseases as stroke, dementia, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis.<sup>1–8</sup> However, the present guidelines focus on oncological patients, who merit special consideration on account of the increasing prevalence of cancer and the interactions between antiepileptic treatment (especially with classic antiepileptic drugs [AED]) and antineoplastic drugs.<sup>1–10</sup> To that end, we performed a systematic literature review of the most important articles, books, and clinical practice guidelines (CPG) published in the last 16 years (taking the PC CPG from the Spanish National Health System's National Plan as the reference document up to 2016, the year of publication of the Spanish Society of Neurology's latest official CPG for epilepsy, as well as the systematic review by Sauro et al.<sup>10</sup> on the current situation of epilepsy guidelines) in order to produce an appropriate model for the management of epileptic seizures in PC. Scientific evidence is classified according to the revised recommendations of the European Federation of Neurological Societies, published in 2004 (Table 1).<sup>11</sup>

## Development

### Definition and objectives of palliative care

The World Health Organization (WHO) defines PC as "an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial, and spiritual." Furthermore, healthcare professionals should build relationships with patients and their families in order to respond to their needs. According to the WHO definition,<sup>1,2</sup> PC: (a) provides relief from pain and other distressing symptoms; (b) affirms life and regards dying as a normal process; (c) intends neither to hasten or postpone death; (d) integrates the psychological and spiritual aspects of patient care; (e) offers a support system to help patients live as actively as possible until death; (f) offers a support system to help the family cope during the patient's illness and in their own bereavement; (g) will enhance quality of life; (h) is applicable early in the course of illness, in conjunction with other therapies that are intended to prolong life, such as chemotherapy or radiation therapy (Fig. 1); and (i) includes those investigations needed to better understand and manage distressing clinical complications.

### Terminal illness<sup>1,5–9,12</sup>

**A. Terminal illness:** a situation of incurable, progressive, advanced-stage disease with no reasonable expectation of response to a specific treatment; which gives rise to such issues as severe, changing, multifactorial symptoms with a great emotional impact on patients, their family members, and care teams; which has a limited vital prognosis; which is associated with significant demand for care; and in which the fundamental objective consists in promoting well-being and quality of life for patients and their families through control of symptoms, emotional support, and


**Table 1** Classification of level of evidence for therapeutic actions.

Level of evidence	Grade of recommendation
<p><b>Level 1</b>  <i>Controlled prospective clinical trials with masked outcome assessment in a representative population</i>  <i>Systematic reviews of controlled clinical trials carried out in a representative population</i>  <i>Both types require the following characteristics:</i>            (a) Randomised sampling            (b) Clearly defined objectives            (c) Clearly defined inclusion/exclusion criteria            (d) Acceptable accounting for dropouts            (e) Baseline characteristics of patients are explicitly described in the text and similar between groups, or any differences have been statistically adjusted.</p>	<p><b>Grade A</b> → <b>Definitively effective, ineffective, or dangerous</b>  <i>Requires at least one conclusive level 1 study or 2 consistent level 2 studies</i>  <b>Grade B</b> → <b>Likely to be effective, ineffective, or dangerous</b>  <i>Requires at least one conclusive level 2 study or 2 consistent level 3 studies</i></p>
<p><b>Level 2</b>  <i>Prospective cohort studies in a representative population with masked outcome assessment and meeting all criteria from a) to e)</i>  <i>Prospective controlled clinical trials with masked outcome assessment in a representative population, but not meeting one of the criteria from a) to e)</i></p>	<p><b>Grade C</b> → <b>May be effective, ineffective, or dangerous</b>  <i>Requires at least 2 conclusive level 3 studies</i></p>
<p><b>Level 3</b>  <i>All other controlled trials in a representative population in which outcome assessment is independent from the treatment administered</i></p>	<p><b>GE-SEN</b> → <b>Potentially effective, ineffective, or dangerous</b>  <i>This recommendation does not meet minimum requirements for a grade C, but it reflects consensus among contributors to the CPG.</i></p>
<p><b>Level 4</b>  <i>Uncontrolled trials, case series, case reports, or expert opinions</i></p>	

CPG: clinical practice guidelines; GE-SEN: Epilepsy Study Group of the Spanish Society of Neurology.  
 Taken with permission from Mercadé Cerdá et al.,<sup>51</sup> 2016.

communication (based on the Spanish National Palliative Care Strategy).<sup>8</sup>

**B. Palliative patient:** a patient with an advanced, progressive, incurable disease for which specific treatment has been optimised as far as possible, who has multiple problems and/or severe symptoms that do not improve despite



**Figure 1** Conceptual, chronological representation of palliative care. PC is implemented alongside curative care following diagnosis of a life-threatening disease. Similarly, even at the final stages of disease, when care is predominantly palliative, there may continue to be a place for curative care. At the final stage of life, curative care ends, and palliative care makes way for terminal care. Finally, the family's bereavement may require specialised care over a prolonged period. Source: Working Group for Clinical Practice Guidelines in Palliative Care.<sup>1</sup> Figure adapted with permission from Koekkoek et al.,<sup>2</sup> 2016.

proper treatment, and whose vital prognosis is limited. They may be oncological or non-oncological patients (Table 2).<sup>6,8</sup>

Epilepsy and cancer.<sup>1-104</sup> Epilepsy affects 0.5% to 1% of the population, with peak incidence during childhood and old age.<sup>26</sup> Seizures are common in PC, especially in patients with brain tumours; up to 88% of patients with glioma (the most frequent type of primary brain tumour) present seizures at some point of tumour progression.<sup>5,78-89,100</sup> Seizure origin appears to be multifactorial, with significant involvement of the healthy peritumoural neuronal tissue.<sup>78,90</sup> Seizure control is essential in the management of these patients, and constitutes a frequent reason for consultation. The impact of seizures on the health system justifies a diagnostic and therapeutic approach centred around appropriate, effective protocols to be implemented in the shortest possible time. It should be taken into account at all times that not all convulsive seizures are epileptic, and not all epileptic seizures are convulsive.<sup>55</sup> Up to 4% of oncological patients have seizures due to other causes (Table 3).<sup>57-64</sup>

Aetiology.<sup>1-106</sup> Central nervous system (CNS) tumours are the most common cause of epilepsy in the 41-60-year age group,<sup>26</sup> making seizures a common, severe complication of cancer. The most frequent cause is intracranial tumour,<sup>52</sup> which is common in cases of dysembryoplastic neuroepithelial tumour (100%); ganglioglioma (80%-90%); primary glial tumours, particularly low-grade glioma (75%),<sup>92,93</sup> which promote epileptogenesis through astrocytic glutamate release<sup>78,90</sup>; meningioma (22%-60%); glioblastoma multiforme (29%-49%); brain metastases (20%-35%); leptomeningeal tumours (10%-15%); and brain primary CNS lymphoma (10%). Seizures are the first semiological manifestation of the tumour in 45% of cases, and are more common in patients with multiple lesions and/or melanoma in histological studies.<sup>65,81,82,100,101</sup> Tumour growth initially generates focal signs; in more than 80% of cases, they are detected subsequently to the diagnosis of primary tumour (metachronous metastasis). They are less frequently diagnosed as the first

manifestation of the disease (synchronous metastasis).<sup>65</sup> As mentioned above, seizures can be caused by multiple factors (Table 2)<sup>1</sup>: (a) *Primary brain tumours and brain metastases*, particularly from lung cancer, breast cancer, or melanoma (multiple lesions are most frequent in the latter case), with brain metastases being less common in prostate, oropharyngeal, or skin cancer; (b) *chemotherapy*, especially at high doses and in the event of liver/kidney failure; (c) *metabolic disorders*, caused either by the tumour itself (hypercalcaemia in lung, prostate, or breast cancer and multiple myeloma) or by drugs (cyclophosphamide-induced hyponatraemia, bisphosphonate-induced hypocalcaemia, cisplatin-induced hypomagnesaemia, etc.); (d) *drugs* (Table 3); (e) *paraneoplastic syndromes*; (f) *cerebrovascular diseases* (stroke, venous sinus thrombosis, etc.; seizures were recorded in 8% of a series of 96 patients with stroke and cancer at the Memorial Sloan Kettering Cancer Center in New York<sup>76</sup>); (g) *CNS infections* (mainly herpesvirus infection); (h) *acquired immunodeficiency syndrome (AIDS)* (cryptococcosis, neurotoxoplasmosis, acute fulminant encephalopathy, etc.)<sup>105,106</sup>; and (i) *cranial radiotherapy* (Table 3).

Clinical manifestation.<sup>1-78</sup> Patients may display different types of seizure and even status epilepticus (SE). Seizure type depends on the speed of tumour growth and the degree of circumscription; temporal, frontal, and parietal tumours most frequently cause focal seizures.<sup>52</sup> SE is rare in patients with brain tumours, but is associated with a mortality rate of 6%-35%.<sup>78</sup>

#### 2010 and 2015 definitions and classifications of the International League Against Epilepsy<sup>7-51,107-116</sup>

A. *Convulsion*: involuntary movement, generally sustained (tonic) or interrupted (clonic), resulting from an alteration in brain function caused by an abnormal, asynchronous, self-limited discharge of CNS neurons.

**Table 2** Criteria for terminal illness in cancer patients and other patients.<sup>6,8</sup>

Cancer patient (the focus of these guidelines)	Non-cancer patient
<ul style="list-style-type: none"> <li>– Presence of an advanced, progressive, incurable oncological disease with a confirmed histological diagnosis, after provision of standard effective treatment. Histological diagnosis is not required in exceptional circumstances in which, given the patient's clinical situation, it is not considered appropriate to perform a comprehensive examination of the tumour; potentially treatable tumours must be excluded.</li> <li>– Low or zero possibility of response to the active, targeted treatment. In certain scenarios, specific resources must be used due to their positive impact on quality of life (oral chemotherapy, radiotherapy, hormone therapy, bisphosphonates, third- or fourth-line drugs, etc.).</li> <li>– Intense, multiple, multicausal, and changing problems or symptoms</li> <li>– Process of dying has an emotional impact on the patient, family, and care team</li> <li>– Specialist opinion that vital prognosis is limited to the last months of life, except in complex clinical situations in which PC is recommended due to an anticipated improvement in quality of life</li> </ul>	<ul style="list-style-type: none"> <li>– Presence of an advanced, progressive disease with no response to medical or surgical treatment</li> <li>– Specific treatment for the underlying disease has been optimised as far as possible. Where a specific treatment exists, it generally must be maintained until the final stage of disease. Replacing specific treatment with palliative care is justified only in the final stage of life.</li> <li>– Intense, multiple, multicausal, and changing problems or symptoms, despite specific treatment, causing repeated emergency department visits, hospital admissions, etc. over a period of 6 months</li> <li>– The explicit or implicit presence of death has an emotional impact on the patient, family, and care team, leading to numerous requests for health care visits to the home, care homes, etc.</li> <li>– Limited vital prognosis: patients closer to the end of life are eligible for specific care. For the majority of diseases, palliative care candidates are identified according to diagnosis and prognosis.</li> </ul> <p><b>Criteria for terminal illness for specific non-oncological conditions</b></p> <ul style="list-style-type: none"> <li>– CHF: CHF symptoms when at rest, despite treatment (including at least one ACE inhibitor and one diuretic); CHF grade IV with LVEF <math>\leq 20\%</math>. Refractory arrhythmia, history of syncope, and/or severe dyspnoea</li> <li>– Chronic respiratory failure and chronic obstructive pulmonary disease: very severe chronic obstructive pulmonary disease (stage IV) with a LVEF <math>&lt; 30\%</math> or a LVEF <math>&lt; 50\%</math> combined with cor pulmonale or right cardiac failure, hypoxaemia at rest with domiciliary oxygen therapy (<math>PO_2 \leq 55</math> mm Hg or <math>O_2</math> saturation <math>\leq 88\%</math>), hypercapnia (<math>PCO_2 &gt; 45</math> mm Hg), weight loss of <math>\geq 10\%</math> over the previous 6 months, and or tachycardia at rest of <math>\geq 100</math> bpm</li> <li>Liver failure: patient not eligible for liver transplant; ascites with no response to fluid restriction or diuretics; bacterial peritonitis; hepatorenal syndrome; hepatic encephalopathy with no response to protein restriction, lactulose, or neomycin; recurrent bleeding due to oesophageal varices despite liver transplant; progressive weight loss; and/or malnutrition</li> <li>– Kidney failure: patient potentially eligible for dialysis but refuses this treatment or kidney transplant; life expectancy less than 6 months; oliguria (<math>&lt; 400</math> mL/24 h); uraemic pericarditis; and/or hepatorenal syndrome</li> <li>– Advanced dementia: very severe cognitive impairment with patient unable to produce meaningful verbal communication, recognise carers, etc.; medical complications arising in the last year, including aspiration pneumonia, urinary tract infections, sepsis, recurrent fever following antibiotherapy, and/or dysphagia</li> <li>– Amyotrophic lateral sclerosis: treatment is always palliative, as the condition causes motor neuron death without affecting sensory neurons, eye muscles, sphincter control, or cognitive function (these patients always meet criteria for PC, regardless of severity).</li> </ul>

ACE: angiotensin-converting enzyme; CHF: chronic heart failure; LVEF: left ventricle ejection fraction; PC: palliative care.



**Table 3** Aetiology of seizures in patients with cancer.*Related to CNS involvement*

- Primary brain tumour
- Brain metastases
- Cerebrovascular diseases
- Reversible posterior leukoencephalopathy syndrome
- Meningoencephalitis
- Leptomeningeal metastases, etc.

*Treatment-related*

- Chemotherapy: cytarabine, methotrexate, cisplatin, bevacizumab, etoposide, interferon alfa, ifosfamide, cyclophosphamide, L-asparaginase, vincristine, interleukin-2, nitrosoureas (carmustine, lomustine), anthracyclines (doxorubicin), etc.
- Toxic/metabolic: kidney failure, liver failure, tumour lysis syndrome, thrombotic thrombocytopenic purpura, hydroelectrolytic disorders, hypoglycaemia, hypoxia/pulmonary embolism, etc.
- Other drugs: pethidine, neuroleptics, bisphosphonates, ondansetron, imipenem, etc.
- Cranial radiotherapy: radiation-induced acute encephalopathy, radiation-induced temporal lobe necrosis, etc.

CNS: central nervous system.

Adapted with permission from Corredera García and Becerra Cuñat,<sup>57</sup> 2012.

**B. Epileptic seizure:** the clinical manifestation of these discharges; focal (partial) seizures involve one hemisphere, whereas generalised seizures involve both. The clinical expression of any epileptic seizure may include impaired consciousness and/or motor, sensory, autonomic, or psychic manifestations perceived by the patient or in many cases by external bystanders. These episodes are usually stereotyped, paroxysmal, brief, and transient or self-limited.<sup>32,44</sup>

**C. Status epilepticus:** the second most common neurological emergency after stroke.<sup>38</sup> SE is of great relevance as it is associated with high rates of morbidity and mortality; prognosis is established in terms of survival.<sup>23</sup> SE is 'a condition characterised by an epileptic seizure that is sufficiently prolonged or repeated at sufficiently brief intervals so as to produce an unvarying and enduring epileptic condition.'<sup>32,44</sup> There are 2 subtypes: (1) *convulsive (CSE)*: epileptic activity characterised by (a)  $\geq 5$  minutes continuous tonic-clonic seizure,  $\geq 10$  minutes focal seizure with altered level of consciousness, or  $\geq 10$ -15 minutes absence seizure; (b)  $\geq 2$  seizures without recovery between seizures; or (c) seizures in clusters ( $\geq 3$  convulsive seizures within 24 h)<sup>32-44,51,111-116</sup>; and (2) *nonconvulsive (NCSE)*: seizure with a continuous abnormal electroencephalography (EEG) trace and no recognisable or predominant motor activity. The typical clinical manifestation of this type of SE is impaired consciousness.

**D. Refractory SE (RSE):** SE persisting despite treatment with 2 indicated AEDs (first- and second-line) at the correct dose, or epileptic activity lasting  $\geq 30$  minutes SE is refractory in 31%-43% of patients, of whom it is necessary in almost half to induce coma in order to control seizures; RSE is associated with a mortality rate of up to 39%.<sup>107</sup>

**E. Super-refractory SE:** epileptic activity lasting  $\geq 24$  hours despite AED treatment.

**F. Epilepsy:** a chronic condition characterised by predisposition to recurrent epileptic seizures ( $\geq 2$  seizures or 1 seizure if a structural lesion is identified via complementary testing, neuroimaging, and/or EEG), with a cognitive and/or psychosocial impact.

**G. Refractory epilepsy:** a situation in which seizure freedom is not achieved after trying at least 2 appropriate AEDs, in monotherapy or in combination, administered correctly, and not withdrawn due to intolerance. Seizure freedom is defined as freedom from seizures for a minimum of 3 times the longest preintervention interseizure interval in the 12 months prior to treatment, or 12 months, whichever period is longest.<sup>14,15</sup> Epilepsy is refractory in 12%-50% of patients with brain tumours, especially low-grade tumours; multidrug resistance genes are thought to be involved.<sup>82</sup>

For practical and treatment purposes, seizures should be classified by their clinical and aetiological characteristics<sup>27-74</sup>: (a) 2010 classification of the International League Against Epilepsy (Table 4)<sup>16,17,27-30,48,49,101</sup>; (b) aetiological classification of seizures (Table 5)<sup>27,31</sup>; (c) 2015 classification of SE.<sup>26-44</sup> Theoretically, there are as many types of SE as there are types of seizure. In clinical practice, we refer to SE and NCSE (Tables 6 and 7).

**Diagnosis.**<sup>1-119</sup> Evidence on the diagnosis and treatment of seizures in patients receiving PC is very scarce; it is therefore necessary to extrapolate from the general population and from patients with cancer.<sup>1</sup> The first step in diagnosing seizures is recognising them as such; they must therefore be distinguished from other types of episodic involuntary muscle contraction (e.g., opioid-induced myoclonus), hyperkinesia (e.g., due to haloperidol or prokinetics), and disorders of consciousness related to increased intracranial pressure, which is observed in 85%-94% of patients.<sup>1,102</sup> A thorough account of the episode is therefore essential. This step is practically simultaneous with therapeutic decision-making. Postictal aetiological diagnosis requires: (a) detailed medical history and physical examination to rule out other non-epileptic conditions (syncope, transient ischaemic attack, psychogenic non-epileptic seizure, transient global amnesia, etc)<sup>20-22</sup>; if epileptic seizure is diagnosed, potential trigger factors should be ruled out: non-adherence and/or changes to AED treatment (the most significant cause in patients with known epilepsy), changes in the sleep-wake cycle, infections, systemic diseases, drugs, ingestion of toxic agents, stress, strobe lighting, menstruation, etc; and (b) laboratory testing (complete blood count and biochemical tests for glycaemia, liver and kidney function including Na, K, Ca, Mg, lactate, etc.; plasma AED levels; urine toxicology; arterial blood gas), EEG, and neuroimaging studies (emergency contrast-enhanced CT scan and preferably a brain MRI scan, given its greater diagnostic sensitivity). It is important to be familiar with the indications for: (1) emergency head CT scan: adult patients with no known epilepsy (always) and epileptic patients with severe head trauma (Glasgow Coma Scale score  $\leq 8$ ), history of stroke or transient ischaemic attack, unknown focal neurological signs, suspected CNS infection, cancer, immunodeficiency (e.g., due to HIV infection), anticoagulant treatment, suspected subarachnoid haemorrhage, or SE with no obvious cause; (2) emergency EEG: prolonged confusional state, coma of unknown origin (NCSE accounts for up to 8% of patients treated in intensive care units [ICU] and 37% of hospitalised

**Table 4** Classification of seizure types according to the 2010 International League Against Epilepsy criteria.<sup>16–18,27–30,50,51,101</sup>

Focal (formerly partial) onset: initial activation of a series of brain networks limited to a localised or more widely distributed area of one hemisphere	Generalised onset: the initial epileptic discharge affects both hemispheres simultaneously. It is also possible for the discharge to originate at some point within bilaterally distributed networks at the cortical or subcortical level but not necessarily the entire cerebral cortex, and spread rapidly.
<p><i>Without impairment of consciousness or awareness (formerly "simple partial seizure" or "rolandic epilepsy")</i></p> <p>— With observable motor (myoclonic, clonic, tonic, atonic, or hypomotor phenomena; versive eye, head, and body movements; spasms; negative myoclonus; or disorders of behavioural inhibition) or autonomic components (horripilation, paleness, tachycardia, nausea, and/or vomiting)</p> <p>— Involving subjective or psychic phenomena (somatosensory, visual, auditory, olfactory, gustatory, or nociceptive phenomena), corresponding to the concept of "aura"</p> <p><i>With impairment of consciousness or awareness; "dyscognitive" (formerly "complex partial seizure" or "temporal lobe epilepsy")</i>: the most frequent type of adult-onset epilepsy. Patients do not respond to applied stimuli and display automotor seizures or automatisms (oroalimentary, mimetic, carpopedal, gestural, dacrytic, vocal, hyperkinetic/hypermotor, etc.).</p> <p>— Evolving to a bilateral, convulsive seizure (formerly "secondarily generalised seizure") with tonic, clonic, or tonic and clonic components<sup>a</sup></p>	<p>Tonic–clonic (formerly "grand mal" seizures, the most common secondary seizure caused by metabolic disorders): onset with motor aura in 15% of cases (e.g., eye/head deviation), followed by a tonic–clonic phase (tonic spasm followed by tonic extension with sudden closure of the mouth, forced exhalation, apnoea, cyanosis, and autonomic signs including increased heart rate and arterial and intravesical pressure, decreased sphincter tone with urinary incontinence, piloerection, facial redness or cyanosis, and/or binocular mydriasis). This is followed by a vibratory phase, then a clonic phase. In the postictal phase, patients display hypotonia, sphincter relaxation, and progressive recovery of level of consciousness (&lt; 30 min). Ictal EEG displays fast rhythms in the tonic phases and slow waves in the clonic phase.</p> <p>— In any combination (myoclonic, myoclonic-atonic, or myoclonic-tonic)</p> <p>Absence seizures</p> <p>— <i>Typical (formerly "petit mal")</i>: a paroxysmal syndrome characterised by short episodes of disconnection from the surroundings with sudden onset and offset (no aura; immediate recovery), during which patients interrupt their activity; patients do not fall or display significant motor phenomena; typical EEG abnormalities are observed. Ictal EEG: 3-Hz spike-wave discharges</p> <p>— <i>Atypical</i>: disconnection from surroundings with less sudden onset and offset, and longer duration. Ictal EEG: irregular spike-wave discharges (2–2.5 Hz).</p> <p>— <i>With special features</i></p> <ul style="list-style-type: none"> <li>• Myoclonic absence</li> <li>• Eyelid myoclonia</li> </ul> <p>Myoclonic: rapid, arrhythmic, involuntary movements; variable localisation (single or multiple; axial, proximal, or distal) and intensity (seizure can be imperceptible or massive, with falls and trauma). Ictal EEG: polyspike-wave complexes and/or sharp waves:</p> <p>— <i>Myoclonic</i></p> <p>— <i>Myoclonic-atonic (formerly "myoclonic-astatic")</i></p> <p>— <i>Myoclonic-tonic</i></p> <p>Clonic: rhythmic muscular jerks; short duration; no locomotor effect. Ictal EEG: fast activity (10 Hz) and slow waves</p> <p>Tonic: rapid-onset, sustained muscle rigidity, principally affecting the upper limbs. EEG: low-voltage fast activity or fast rhythms (9–10 Hz)</p> <p>Atonic (formerly "drop attacks" or "astatic seizures"): rapid loss of flexor and extensor muscle tone in the neck, trunk, and limbs, resulting in falls onto the gluteus muscles, propulsion or retropulsion, or simple head nods. Ictal EEG: slow spike-wave activity, decreased amplitude, and/or desynchronisation</p>

Another section will address seizures that are unclassifiable due to incomplete or inadequate data, or which do not coincide with the described classification. These include neonatal seizures (e.g., rhythmic eye, chewing, or swimming movements), according to the terminology of the 1981 ILAE classification, and epileptic spasms according to the 2010 document. In the 2010 classification, Berg et al.<sup>28</sup> stress the importance of precisely describing seizures, addressing motor, cognitive, autonomic, and/or sensory/subjective manifestations. When these occur sequentially, the order of the different manifestations should also be recorded. Focal motor seizures are the predominant type of seizure observed in patients with brain metastases.<sup>90</sup>

EEG: electroencephalography.

<sup>a</sup> According to the 2016 ILAE operational classification, there may be a progression to "bilateral tonic–clonic" seizure.<sup>30</sup>

**Table 5** American College of Emergency Physicians aetiological classification of seizures.<sup>22,27,31</sup>

Provoked seizures		Unprovoked seizures
ASS	RSS	Undetermined aetiology
<i>ASS with acute lesion<sup>a</sup></i>	<i>Seizures with subacute/chronic lesions<sup>a</sup></i>	<i>Idiopathic seizures<sup>b</sup></i>
– Post-trauma (head trauma, surgery) in the first week	– Malformations, congenital and perinatal lesions	– Personal history
– Haemorrhagic > ischaemic stroke in the first week	– Long-standing stroke	– Affected by age
– CNS infection in the first week	– Residual brain lesions (scarring, gliosis, malacia)	– Promoting factors (↓ epileptogenic threshold)
	– Cerebral space-occupying lesions	
	– Degenerative changes	
<i>Toxic/metabolic ASS<sup>b</sup></i>		<i>Cryptogenic seizures<sup>a</sup></i>
– Drugs and toxic agents		– Probably symptomatic
– Metabolic imbalance		– Aetiological study should be broadened

ASS: acute symptomatic seizure; CNS: central nervous system; RSS: remote symptomatic seizure.

Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

<sup>a</sup> Typically focal onset seizures.

<sup>b</sup> Generalised seizures.

patients with coma and no clinical manifestation of epileptic activity),<sup>22,41,117</sup> delayed recovery of level of consciousness after SE, brief episodes of loss of consciousness of unknown origin (rule out absence seizures), acute seizures following trauma (which increase the risk of post-traumatic epilepsy if an irritative zone is observed in the acute-phase [1st week] EEG),<sup>118</sup> and/or herpes simplex encephalitis (observation of periodic, lateralised discharges assists in diagnosis; however, these discharges are also observed in patients with stroke, tumours, postanoxic encephalopathy, etc.)<sup>119</sup>; in cases of high clinical suspicion in which the first EEG showed normal results, it is recommended to perform a sequence including a second EEG, a sleep-deprived EEG, a sleep EEG, and a long-term video-EEG<sup>26</sup>; and (3) lumbar puncture: in the absence of radiological lesions or metabolic causes, lumbar puncture should be performed to rule out infection and/or meningeal carcinomatosis. Diagnostic tests should be selected according to the patient's condition and the preferences of the patient and his/her family.

### Treatment<sup>1–160</sup>

**Antiepileptic drugs.**<sup>27,31</sup> AEDs are currently the main treatment for epilepsy and seizures. Treatment is symptomatic, as no antiepileptogenic drugs are yet available. Table 8 summarises the main mechanisms of action of AEDs, in order to better explain the indications and possible combinations of these drugs:

**Ideal antiepileptic drug.**<sup>27,31</sup> The criteria for selecting an "ideal AED" in emergency departments are: (a) *good pharmacological profile*: completely and rapidly absorbed via oral route, linear kinetics, low plasma protein binding, extrahepatic metabolism, absence of active metabolites and interactions, renal clearance, and long half-life. In accordance with these criteria, the AEDs with the best pharmacokinetic profiles are levetiracetam (LEV),

lacosamide (LCM), gabapentin (GBP), and pregabalin (PGB). Drugs with an intermediate pharmacokinetic profile are eslicarbazepine (ESL), lamotrigine (LTG), oxcarbazepine (OXC), retigabine (RTG), topiramate (TPM), zonisamide (ZNS), and rufinamide (RFN). Finally, the AEDs with the worst kinetics are phenytoin (PHT), carbamazepine (CBZ), valproic acid (VPA), felbamate (FBM), primidone (PRM), and tiagabine (TGB). (b) *Parenteral administration, comfortable oral conversion, and possibility of sequential therapy*: AEDs must be suitable for parenteral administration (preferably intravenously [IV]). Eighty-five percent of terminally ill patients display dysphagia,<sup>85,89</sup> including dysphagia caused by decreased level of consciousness due to the progression of the tumour in the brain and/or adverse drug reactions.<sup>85,89,102,103</sup> Parenteral administration enables therapeutic levels to be reached quickly, both in patients with SE and for acute-phase preventive treatment. Where possible, it is desirable to comfortably continue administering the same drug orally (1:1 conversion) and safely at therapeutic doses. Of the AEDs that can be administered intravenously, LEV and LCM meet this criterion. VPA is the next drug of choice, preferable to PHT and anaesthetics. (c) *Broad spectrum of action*: ideally, the AED selected will be able to control both focal and generalised seizures; because there are often no witnesses to seizures, they are often poorly defined, with unclear medical history. There must also be no risk of exacerbating any specific type of seizure; CBZ and PHT, for example, exacerbate myoclonic and absence seizures (Table 9). LEV, LTG, VPA, TPM, and ZNS meet this criterion. In patients with clearly focal onset seizures, LEV, LTG, or OXC are recommended as the treatment of first choice, and ZNS, CBZ, TPM, GBP, LCM, or ESL as alternatives. In patients with generalised seizures, VPA is preferred for tonic-clonic, myoclonic, or absence seizures, LEV for tonic-clonic or myoclonic seizures, and LTG for



**Table 6** (A) Classical classification of status epilepticus.<sup>19,27–37,51</sup> (B) Salzburg consensus criteria for nonconvulsive status epilepticus.

(A) SE	CSE	NCSE
<i>Partial onset</i>	<ul style="list-style-type: none"> <li>– Simple partial motor</li> <li>– Secondly generalised tonic–clonic</li> <li>– Epilepsia partialis continua (rhythmic or pseudorhythmic motor semiology)</li> </ul>	<ul style="list-style-type: none"> <li>– Non-motor simple partial (sensory, autonomic, psychic phenomena, etc.)</li> <li>– Complex partial (more frequent in frontal and temporal lobe epilepsy)</li> </ul>
<i>Generalised</i>	<ul style="list-style-type: none"> <li>– Tonic</li> <li>– Clonic</li> <li>– Tonic–clonic</li> <li>– Myoclonic</li> </ul>	<ul style="list-style-type: none"> <li>– Typical and atypical absence</li> <li>– Subtle<sup>a</sup></li> <li>– Patients in coma with epileptiform EEG activity (electroclinical dissociation [low level of consciousness and no motor activity, with EEG pattern characteristic of seizure])</li> </ul>
<b>(B) EEG diagnosis of NCSE<sup>b</sup></b>		
<i>Patients without known epileptic encephalopathy</i>	EDs > 2.5 Hz, or  EDs ≤ 2.5 Hz or rhythmic delta/theta activity (> 0.5 Hz) and at least one of: – Improvement of EEG and clinical features with IV AEDs <sup>c</sup> , or – Subtle ictal clinical phenomena, or – Typical ictal spatiotemporal evolution <sup>d</sup>	
<i>Patients with known epileptic encephalopathy</i>	In addition to the criteria listed above, patients must display at least one of: – Increase in prominence or frequency when compared to baseline with observable change in clinical state – Improvement of clinical and EEG features with IV AEDs <sup>c</sup>	

CSE: convulsive status epilepticus; ED: epileptiform discharge; EEG: electroencephalography; IV AED: intravenous antiepileptic drug; NCSE: nonconvulsive SE; SE: status epilepticus.

<sup>a</sup>Subtle NCSE: subtle motor activity following the ictal epileptiform activity after offset of evident motor activity following untreated or undertreated generalised CSE. Characterised by minor motor signs (facial and/or distal clonic movements, nystagmus, eye deviation, etc.). These seizures usually manifest in severely ill patients in ICUs, with a severely reduced level of consciousness (generally in coma) and focal brain injury; mortality can reach 65%. It is therefore essential to open these patient's eyes in order to detect the condition.<sup>39,40</sup> Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

<sup>b</sup> Diagnosis of NCSE should be based on the combination of clinical and EEG findings. Clinical signs lasting ≥ 10 min indicate possible NCSE.

<sup>c</sup> NCSE should be suspected if EEG improvements are not associated with clinical improvements, or fluctuate with no defined progression.

<sup>d</sup> Initial increase (increase in voltage and change in frequency), progression of EEG pattern (change in frequency [ $> 1$  Hz] or localisation), or decrementing termination (voltage or frequency).

Taken with permission from Trinkka and Kälviäinen,<sup>44</sup> 2016.

tonic–clonic or absence (but not myoclonic) seizures. [Table 8](#) shows the mechanisms of action of the different AEDs; [Table 9](#) shows their efficacy according to seizure and epilepsy type. (d) *Safety* is a fundamental consideration. AEDs must be well tolerated, with no significant adverse reactions or drug–drug interactions, including with other AEDs, and must be suitable for use in specific clinical contexts (old age; women of childbearing age; heart, liver, or kidney comorbidities, etc). Based on current evidence from case series, retrospective studies, and expert opinions, monotherapy with LEV, LTG, OXC, TPM, VPA, and GPB and combined therapy with LCM, perampanel, and brivaracetam

(BRV) are recommended in these situations, with exceptions. PHT and phenobarbital (PB) should be avoided, and CBZ and VPA should not be administered to patients with liver disease or polymedicated individuals. GBP, CBZ and derivatives, TPM, LEV, BRV, and LCM should be administered with caution (adjusted doses) in patients with kidney failure ([Tables 10 and 11](#)).<sup>27,45–49,59–63,74,80,89,96,100,152–159</sup>

Use of AEDs in PC.<sup>22–159</sup> Epileptic seizures are common in patients with brain tumours; seizure control is an important objective in the management of these patients. Patients with brain tumours are more likely to develop refractory epilepsy. The main issues of AED use in these patients

**Table 7** 2015 International League Against Epilepsy classification of status epilepticus.<sup>32–44</sup>

Axis I: semiology	Axis II: aetiology
<b>With prominent motor symptoms</b>	
A.1 Convulsive SE (CSE, synonym: tonic–clonic SE)	<i>Known</i> – Acute (e.g. stroke, intoxication, malaria, encephalitis, etc.) – Remote (e.g., post-traumatic, postencephalitic, poststroke, etc.) – Progressive (e.g., brain tumour, Lafora's disease and other PMEs, dementias) – SE in defined electroclinical syndromes <i>Unknown (i.e., cryptogenic)</i> Axis III: electroencephalographic correlates (1) Location: generalised (including bilateral synchronous patterns), lateralised, bilateral independent, or multifocal (2) Name of the pattern: periodic discharges, rhythmic delta activity, or spike–slow wave/sharp wave–slow wave complexes, plus subtypes, etc. <sup>a</sup> (3) Morphology: sharpness, number of phases (e.g., triphasic morphology), absolute and relative amplitude, polarity (4) Time-related features: prevalence, frequency, duration, daily pattern duration and index, onset (sudden vs gradual), and dynamics (evolving, fluctuating, or static) (5) Modulation: stimulus-induced vs spontaneous (6) Effect of intervention (medication) on EEG
A.1.a Generalised convulsive	
A.1.b Focal onset evolving into bilateral convulsive SE	
A.1.c Unknown whether focal or generalised	
A.2 Myoclonic SE (prominent epileptic myoclonic jerks)	
A.2.a With coma	
A.2.b Without coma	
A.3 Focal motor	
A.3.a Repeated focal motor seizures (Jacksonian)	
A.3.b EPC	
A.3.c Adversive SE	
A.3.d Oculoclonic SE	
A.3.e Ictal paresis (e.g., focal inhibitory SE)	
A.4 Tonic SE	
A.5 Hyperkinetic SE	
<b>Without prominent motor symptoms (i.e., NCSE)</b>	
B.1 NCSE with coma (including so-called "subtle" SE)	Axis IV: age (1) Neonatal (0 to 30 days) (2) Infancy (1 month to 2 years) (3) Childhood (2 to 12 years) (4) Adolescence and adulthood (12 to 59 years) (5) Elderly ( $\geq 60$ years)
B.2 NCSE without coma	
B.2.a Generalised	
B.2.a.a Typical absence SE	
B.2.a.b Atypical absence SE	
B.2.a.c Myoclonic absence SE	
B.2.b Focal	
B.2.b.a Without impairment of consciousness (aura continua, with autonomic, sensory, visual, olfactory, gustatory, emotional/psychic/experiential, or auditory symptoms)	
B.2.b.b Aphasic SE	
B.2.b.c With impaired consciousness	
B.2.c Unknown whether focal or generalised	
B.2.c.a Autonomic SE	

SE is a condition resulting either from the failure of the mechanisms responsible for termination of seizure or from the initiation of mechanisms responsible for prolonged seizures (after time point  $t_1$ ). Depending on the type and duration of the seizure, the long-term consequences of SE (after time point  $t_2$ ) may include neuronal death, neuronal damage, and the alteration of neural networks. This conceptual definition involves 2 time dimensions. The first is the duration of the seizure and the time point ( $t_1$ ) after which seizure can be considered "abnormally prolonged," and at which point AEDs should be administered, established as 5 min for generalised tonic–clonic SE, 10 min for focal SE (with or without impaired level of consciousness), and 10–15 min for absence SE. Time point ( $t_2$ ), from which point continued epileptic activity may entail a risk of long-term consequences, is established at 30 min for generalised tonic–clonic SE.<sup>32,44</sup>

NB: although generalised convulsive or nonconvulsive SE with coma corresponds almost perfectly to the semiological classification of SE, focal SE is notoriously variable and appears to be better described in the new ILAE classification by Trinka's<sup>32</sup> study group, who provide more clinically relevant subdivisions and different mortality rates. This enhanced knowledge enables the development of more precise prognostic scales than the existing clinical tools; these should be taken into account in future epidemiological studies into SE.<sup>42</sup>

AED: antiepileptic drug; EEG: electroencephalography; EPC: epilepsia partialis continua; ILAE: International League Against Epilepsy; NCSE: nonconvulsive SE; PME: progressive myoclonic epilepsy; SE: status epilepticus.

<sup>a</sup> Plus subtypes feature additional characteristics, making the EEG trace appear more ictal than the normal (not plus) pattern (not applicable to sharp waves).<sup>160</sup>

Adapted with permission from Trinka et al.,<sup>32</sup> 2015.

are the following<sup>54</sup>: (a) *drug–drug interactions*<sup>57,58</sup>: there are numerous CYP450-mediated drug–drug interactions between AEDs and chemotherapeutic agents. Within the group of AEDs, some drugs have high potential to provoke interactions (CBZ, PHT, PB, PRM, VPA, and FBM affect other drugs and are themselves affected) while others have medium or low potential (LTG, OXC, TGB, TPM, ESM, clonazepam [CNZ], clobazam [CLB], and ZNS do not affect other drugs but are themselves affected; LCM, VGB,

GBP, LEV, and PGB do not affect other drugs and are not themselves affected); the latter group are ideal for use in PC (Table 12).<sup>57–64</sup> Finally, seizures may occur at onset of radio- or chemotherapy (e.g., with carmustine wafer, intra-arterial cisplatin, etc.) due to neural irritation of the surrounding brain tissue.<sup>90</sup> (b) *Haematologic toxicity*: neutropaenia and thrombocytopaenia associated with classic AEDs are rare (0.9–1.2 cases per 10<sup>4</sup> prescriptions), although coadministration with cytostatic drugs is associated with

**Table 8** Antiepileptic drugs and their mechanisms of action.<sup>27,49,90,154–158</sup>

AEDs by generation	Mechanism of action (+++, strong action; ++, medium action; +, weak action)						
	Inhibit excitation			Activate inhibition		Other	
	Sodium channel	Calcium channel	Glutamatergic excitation	Potassium channel	GABAergic inhibition	SV2A binding	Selective, non-competitive blocking of AMPA-type ionotropic glutamate receptors
<i>1st generation</i>							
Phenytoin	+++	+					
Phenobarbital			+		+++		
Carbamazepine	+++	+					
Valproic acid	+	+	+		++		
Ethosuximide		+++					
<i>2nd generation</i>							
Lamotrigine	+++	+					
Topiramate	++	++	++		++		
Gabapentin	+	+			++		
Pregabalin		++	+				
Oxcarbazepine	+++	+		+			
Levetiracetam		+	+	+	+	+	
Zonisamide	++	++					
Vigabatrin					+++		
Felbamate	+	+	+		+		
Tiagabine					+++		
<i>3rd generation</i>							
Lacosamide	+++						
Eslicarbazepine	+++						
Retigabine				++	+		
Rufinamide	++						
Perampanel							+
Brivaracetam						+++	

AED: antiepileptic drug; AMPA:  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; SV2A: synaptic vesicle glycoprotein 2A (involved in neurotransmitter vesicle fusion and exocytosis). Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

**Table 9** Efficacy and indications for antiepileptic drugs.<sup>27,49,97,154–158</sup>

AED	Focal- or partial-onset seizures	Generalised-onset seizures			Epileptic syndromes
		Tonic-clonic	Myoclonic	Absence	
<i>1st generation</i>					
Phenytoin	+ <sup>a</sup>	+ <sup>a</sup>	–	–	– LGS, – LKS
Phenobarbital	+ <sup>a</sup> SE	+ <sup>a</sup> SE		+	
Carbamazepine	+ <sup>a</sup>	+ <sup>a</sup>	–	–	– DS, – LGS, – LKS
Valproic acid	+ <sup>a</sup>	+ <sup>a</sup>	+ <sup>a</sup>	+ <sup>a</sup>	– RE
Ethosuximide				+ <sup>a</sup>	
<i>2nd generation</i>					
Lamotrigine	+ <sup>a</sup>	+ <sup>a</sup>	+?	+	+ <sup>a</sup> LGS, – DS, – RE
Topiramate	+ <sup>a</sup>	+ <sup>a</sup>	+ <sup>a</sup>		+ <sup>a</sup> LGS
Gabapentin	+ <sup>a</sup>	+?	–	–	– LGS
Pregabalin	+ <sup>b</sup>	+?			
Oxcarbazepine	+ <sup>a</sup>	+	–	–	– DS, – LGS, – LKS
Levetiracetam	+ <sup>a</sup>	+ <sup>b</sup>	+ <sup>b</sup>		
Zonisamide	+ <sup>b</sup>	+?	+?	+?	+? LGS
Vigabatrin	+ <sup>b</sup>	+?	–	–	+ <sup>a</sup> West, – LGS
Tiagabine	+ <sup>b</sup>	+?	–	–	
<i>3rd generation</i>					
Lacosamide	+ <sup>b</sup>		+?		
Eslicarbazepine	+ <sup>b</sup>	+?	–	–	– DS, – LGS, – LKS
Retigabine	+ <sup>b</sup>				
Rufinamide	+	+	+?	+?	+ <sup>b</sup> LGS
Perampanel	+ <sup>b</sup>	+ <sup>b</sup>			+ <sup>b</sup> IGE
Brivaracetam	+ <sup>b</sup>				

AED: antiepileptic drug; DS: Dravet syndrome; IGE: idiopathic generalised epilepsy; LGS: Lennox–Gastaut syndrome; LKS: Landau-Kleffner syndrome; RE: rolandic epilepsy; SE: status epilepticus only; +: effective; +?: uncertain effectiveness; –: harmful.

<sup>a</sup> Indicated in monotherapy.

<sup>b</sup> Indicated as adjuvant treatment.

Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

greater toxic effects.<sup>27–65,67,68,94</sup> (c) *CNS toxicity*: it is essential to thoroughly assess the adverse effects of AEDs on the CNS, as they are more frequent in patients with brain tumours than in those without; the sedation, cognitive alterations, changes in personality, and occasionally the focal neurological signs that these drugs can cause may be misinterpreted as tumour progression and/or cause the patient's overall condition to worsen. (d) *Hypersensitivity syndrome*: radiotherapy is associated with greater incidence of this toxic effect.<sup>51–74</sup> These patients may present malnutrition with hypoproteinaemia, which can result in a higher than expected fraction unbound in plasma for classic AEDs, promoting toxic effects.<sup>57</sup>

*Risk of allergic reactions or other types of adverse reactions*.<sup>57</sup> Patients with brain tumours are at much greater risk of adverse reactions to AEDs than other epileptic patients. AEDs are associated with such severe adverse reactions as Stevens–Johnson syndrome, especially during dose up-titration (first 4–8 weeks); these effects have been described for CBZ, PHT, PB, VPA, LMT, ESM, TPM, GBP, ZNS, TGB, and FBM. Stevens–Johnson syndrome has also been reported in patients receiving cranial radiotherapy simultaneously with PHT, CBZ, and/or PB. Given the increased risk of cutaneous adverse reactions, AEDs are not recommended for patients receiving whole-brain radiotherapy. Patients with brain tumours and receiving

AEDs and radiotherapy more frequently present cognitive adverse reactions. Patients receiving both treatments simultaneously have shown 6 times greater impairment in neuropsychological tests (attention deficit, psychomotor delay, and/or alterations in executive function) than patients receiving radiotherapy only, in both medium- and long-term assessments. Other frequent adverse reactions include increased incidence of headache (PHT, LEV, ZNS), myelosuppression (CBZ, LMT), cognitive and behavioural alterations (TPM, LEV, PHT, PB, CBZ, LMT), poor coordination (PHT), and increased risk of shoulder-hand syndrome (hemiplegic patients receiving PB). To summarise, patients with brain tumours receiving chemotherapy, radiotherapy, or corticosteroids should not be treated with classic AEDs due to possible interactions and/or idiosyncratic adverse reactions (level of evidence: 4).<sup>51</sup>

*Therapeutic approach*.<sup>27,32,66–70</sup> Acute treatment of epileptic seizures in patients receiving PC should be symptomatic and aetiological. It is essential to resolve situations entailing vital risk (obstructed airway, intracranial hypertension, etc.) and which may reduce quality of life (incoercible vomiting, refractory pain, etc). The following considerations must be observed when treating these patients, especially if they are terminally ill: (1) *symptom control* will be the main aim of emergency treatment. When necessary, and in situations in which it is indicated, administration of opioids

**Table 10** Antiepileptic drugs used in patients (particularly cancer patients) receiving palliative care: interactions, secondary effects, and contraindications.<sup>27,45,46,49,60–64,75,81,90,97,101,154–159</sup>

AED	Dose	Interactions with		Adverse effects		Contraindications
		Other AEDs	Other drugs	Pharmacological (dose-dependent)	Idiosyncratic (dose-independent)	
<i>1st generation</i>						
Phenobarbital (Gardenal <sup>®</sup> , Luminal <sup>®</sup> , Luminaletas <sup>®</sup> )	Loading dose of 10-20 mg/kg, then 1-3 mg/kg/day (24 h intervals) (TPC: 10–40 µg/mL)	↓ CBZ, VPA, ESM, LMT, TGB, TPM, OXC, ZNS, ESL, RFN; ↑↓ PHT	OC, oral anticoagulants, TCA	Drowsiness, respiratory depression, vertigo, cognitive alterations, hyperactivity, frozen shoulder, Dupuytren contracture, reduced libido, sedation	Skin rash or eruption (including Stevens–Johnson syndrome), myelosuppression (megaloblastic anaemia) (rare), hepatotoxicity (rare), hypersensitivity, agranulocytosis	Allergy to the compound, <sup>b</sup> elderly patients, respiratory failure, porphyria, pregnancy. FDA: pregnancy category D risk
PHT (Epanutin <sup>®</sup> , Sinergina <sup>®</sup> )	Loading dose of 10-20 mg/kg, then 3-5 mg/kg/day (24-h intervals) (TPC: 10–20 µg/mL)	↓ CBZ, VPA, ESM, LMT, TGB, TPM, OXC, ZNS, ESL, RFN; ↑↓ PB	OC, oral anticoagulants, digoxin, diuretics, corticosteroids, chemotherapeutic agents, H <sub>2</sub> antagonists, levodopa, methadone, salicylates	Drowsiness, vertigo, gingival hyperplasia, hirsutism, exanthema, ataxia, cognitive alterations, cardiorespiratory depression, neuropathy, cerebellar degeneration, osteomalacia, systemic lupus erythematosus, lymphadenopathies	Skin rash or eruption (including Stevens–Johnson syndrome), myelosuppression (aplastic anaemia), hepatotoxicity, folate deficiency, hypersensitivity syndrome	Allergy to the compound, <sup>b</sup> sinus bradycardia, atrioventricular block, pregnancy. FDA: pregnancy category D risk
CBZ (Tegretol <sup>®</sup> )	400-2400 mg/day (6-12-h intervals) (TPC: 4-12 µg/mL)	↓ VPA, ESM, LMT, TGB, TPM, OXC, ZNS, RFN; ↑↓ PB and PHT	OC, oral anticoagulants, salicylates, lithium compounds, haloperidol, hydrochlorothiazide, fluoxetine, opiates, antiviral drugs, calcium channel blockers	Exanthema, diplopia, ataxia, vertigo, leukopaemia, hyponatraemia, weight gain, arrhythmia	Agranulocytosis, skin rash or eruption (including Stevens–Johnson syndrome), aplastic anaemia, hepatotoxicity, hypersensitivity syndrome, pancreatitis	Allergy to the compound, <sup>b</sup> atrioventricular block, treatment with MAO inhibitors in the previous 2 weeks, pregnancy. FDA: pregnancy category D risk



Table 10 (Continued)

AED	Dose	Interactions with		Adverse effects		Contraindications
		Other AEDs	Other drugs	Pharmacological (dose-dependent)	Idiosyncratic (dose-independent)	
VPA (Depakine <sup>®</sup> )	15-60 mg/kg/day (6-12-h intervals) (TPC: 50-100 µg/mL)	↑ PB, CBZ, VPA, ESM, LMT, TGB, TPM, OXC, ZNS, RFN; ↑↓ PB and PHT	Aciclovir, amitriptyline, salicylates, chemotherapeutic agents, erythromycin, methotrexate, antacids	Drowsiness, nausea, tremor, thrombocytopenia, ecchymosis, weight gain, alopecia, hyperammonaemic encephalopathy	Skin rash or eruption (including Stevens–Johnson syndrome), hepatotoxicity, hypersensitivity syndrome, pancreatitis	Allergy to the compound, <sup>b</sup> hepatitis, hepatic porphyria, liver disease, branched-chain amino acid metabolism disorders, pregnancy
ESM (Zarontin <sup>®</sup> )	500-2000 mg/day (8-12-h intervals) (TPC: 40-100 µg/mL)	—	Isoniazid	Hiccough, visual and gastrointestinal alterations	Agranulocytosis, Stevens–Johnson syndrome, aplastic anaemia, hypersensitivity syndrome	Myasthenia gravis, porphyria, pregnancy. FDA: pregnancy category D risk
<i>2nd generation</i>						
LTG (Crisomet <sup>®</sup> , Labileno <sup>®</sup> , Lamictal <sup>®</sup> , Lavinol <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC: 2.5-15 µg/mL)	↑ CBZ; ↓ VPA	OC	Exanthema, ataxia, diplopia, headache, sleep disorders	Stevens–Johnson syndrome, hepatotoxicity, pancreatitis, aplastic anaemia, hypersensitivity syndrome	Allergy to the compound, <sup>b</sup> pregnancy. FDA: pregnancy category C risk
TPM (Acromicil <sup>®</sup> , Epilmax <sup>®</sup> , Topamax <sup>®</sup> , Topibrain <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC: 5-20 µg/mL)	↑ CBZ; ↓ VPA	Oral antidiabetic drugs, digoxin, amitriptyline, OC, hydrochlorothiazide, lithium	Drowsiness, fatigue, anorexia, paraesthesias, cognitive alterations, hypohidrosis, psychosis, glaucoma	Drowsiness, tiredness, overweight	Stevens–Johnson syndrome, hepatotoxicity, pancreatitis
Gabapentin (Gabatur <sup>®</sup> , Gabmylan <sup>®</sup> , Neurontin <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC: 2-20 µg/mL)	↑ FBM	Antacids, morphine	Drowsiness, tiredness, overweight	Stevens–Johnson syndrome, hepatotoxicity	Allergy to the compound, <sup>b</sup> breastfeeding, pregnancy. FDA: pregnancy category C risk
Pregabalin (Lyrica <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC <sup>3</sup> )	—	Antacids, morphine	Hyperactivity, tiredness, overweight	Peripheral oedema	Allergy to the compound, <sup>b</sup> breastfeeding, pregnancy. FDA: pregnancy category C risk
OXC (Trileptal <sup>®</sup> , Oxcarmylan EFG <sup>®</sup> )	1200-2400 mg/day (6-12-h intervals) (TPC: 3-35 µg/mL)	↑ PHT and PB	OC, diuretics	Drowsiness, exanthema, vertigo, diplopia, headache, ataxia, dyspepsia, gastrointestinal alterations, hyponatraemia	Neutropaenia, hepatotoxicity, hypersensitivity syndrome	Allergy to the compound, <sup>b</sup> atrioventricular block, treatment with MAO inhibitors in the previous 2 weeks, pregnancy. FDA: pregnancy category C risk
Levetiracetam (Keppra <sup>®</sup> , Laurak <sup>®</sup> , Tirbas <sup>®</sup> , Vetira <sup>®</sup> )	1000-3000 mg/day (12-h intervals) (TPC: 12-46 µg/mL)	—	Probenecid, rifampicin	Drowsiness, vertigo, headache, anorexia, irritability, psychosis	Nephrotoxicity, hepatotoxicity, pancreatitis	Allergy to the compound, <sup>b</sup> pregnancy. FDA: pregnancy category C risk

Table 10 (Continued)

AED	Dose	Interactions with		Adverse effects		Contraindications
		Other AEDs	Other drugs	Pharmacological (dose-dependent)	Idiosyncratic (dose-independent)	
ZNS (Zonegran <sup>®</sup> )	10-20 mg/day (8-h intervals) (TPC: 10-40 µg/mL)	—	Rifampicin	Drowsiness, asthenia, anorexia, cognitive and affective alterations, psychosis, nephrolithiasis, hypohidrosis, paraesthesias	Stevens–Johnson syndrome	Allergy to the compound or to sulphonamides, <sup>b</sup> pregnancy. FDA: pregnancy category C risk
Vigabatrin (Sabrilix <sup>®</sup> )	500-3000 mg/day (12-h intervals) (TPC: 10-40 µg/mL)	↓ PHT and RFN	—	Affective and behavioural alterations, weight gain, concentric visual field defect	Hepatotoxicity, pancreatitis	Allergy to the compound, <sup>b</sup> pregnancy. FDA: pregnancy category C risk
TGB (Gabitril <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC: 0.02-0.2 µg/mL)	↓ VPA	Cimetidine	Vertigo, abdominal pain, headache, drowsiness, affective alterations, psychosis	Stevens–Johnson syndrome	Allergy to the compound, <sup>b</sup> age < 12 years, acute liver failure, pregnancy. FDA: pregnancy category C risk
FBM (Taloxa <sup>®</sup> )	1200-3600 mg/day (6–8-h intervals) (TPC: 30-60 µg/mL)	↑ VPA, CBZ, PHT	Barbiturates	Drowsiness, headache, dizziness, ataxia, diplopia, nausea, abdominal pain, constipation	Stevens–Johnson syndrome, hepatotoxicity, aplastic anaemia	Allergy to the compound, <sup>b</sup> age < 4 years, acute liver failure, breastfeeding, pregnancy. FDA: pregnancy category C risk
Primidone (Mysoline <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC: 5-10 µg/mL)	Similar to PHB	Similar to PHB	Similar to PHB	Similar to PHB	Similar to PHB
3rd generation Lacosamide (Vimpat <sup>®</sup> )	750-2000 mg/day (8-h intervals) (TPC <sup>a</sup> )	—	Class I antiarrhythmics (quinidine, procainamide, PHT, lidocaine, propafenone, flecainide)	Dizziness, drowsiness, headache, diplopia, ataxia, tremor, nystagmus, affective and gastrointestinal alterations, prolonged PR interval, atrial fibrillation, atrial flutter	Multi-organ hypersensitivity reactions (eosinophilia, hepatitis, nephritis, lymphadenopathy, and/or myocarditis)	Allergy to the compound <sup>b</sup> or to soya lecithin, age < 16 years, atrioventricular block, pregnancy. FDA: pregnancy category C risk
ESL (Zebinix <sup>®</sup> )	400-1200 mg/day (24-h intervals) (TPC <sup>a</sup> )	↑ PHT and PB; ↓ LTG and TPM	OC, oral anticoagulants, MAO inhibitors, simvastatin	Headache, drowsiness, dizziness, ataxia, diplopia, nausea, and hyponatraemia	—	Allergy to the compound, <sup>b</sup> age < 18 years, 2nd/3rd degree atrioventricular block, pregnancy. FDA: pregnancy category C risk

Table 10 (Continued)

AED	Dose	Interactions with		Adverse effects		Contraindications
		Other AEDs	Other drugs	Pharmacological (dose-dependent)	Idiosyncratic (dose-independent)	
Retigabine (Trobal <sup>®</sup> )	100-1200 mg/day (8-h intervals) (TPC <sup>a</sup> )	—	Anaesthetics, digoxin	Drowsiness, dizziness, confusion, dysarthria, psychosis, hallucinations, exanthema, blurred vision, prolonged QT interval, skin and eye pigmentation (decolouration), acquired vitelliform maculopathy	Urinary retention, urinary tract infections, haematuria	Allergy to the compound, <sup>b</sup> age < 18 years, pregnancy. FDA: pregnancy category C risk
RFN (Inovelon <sup>®</sup> )	400-4800 mg/day (12-h intervals) (TPC <sup>a</sup> )	↑ PHT and PB; ↓ LTG and CBZ	OC	Drowsiness, headache, vomiting, anorexia, fatigue, reduced QT interval	Multi-organ hypersensitivity reactions (eosinophilia, hepatitis, nephritis, lymphadenopathy, and/or myocarditis)	Allergy to the compound <sup>b</sup> or derivatives, breastfeeding, pregnancy. FDA: pregnancy category C risk
Perampanel (Fycompa <sup>®</sup> )	4-12 mg/day (24-h intervals) (TPC <sup>a</sup> )	—	OC	Drowsiness, dizziness, fatigue, vertigo, ataxia, anorexia or hyperorexia, weight gain, irritability, aggressiveness, anxiety, confusion, blurred vision, diplopia, mood swings, suicidal thoughts	—	Allergy to the compound, <sup>b</sup> lactose intolerance, breastfeeding, pregnancy. FDA: pregnancy category C risk
Brivaracetam (Briviact <sup>®</sup> )	50-200 mg/day (12-h intervals) (TPC <sup>a</sup> )	—	Rifampicin	Drowsiness, vertigo, headache, fatigue	Nephrotoxicity, hepatotoxicity	Allergy to the compound, <sup>b</sup> pregnancy. FDA: pregnancy category C risk

AED: antiepileptic drug; CBZ: carbamazepine; ESL: eslicarbazepine; ESM: ethosuximide; FBM: felbamate; FDA: United States Food and Drug Administration; LTG: lamotrigine; MAO: monoamine oxidase; OC: oral contraception; OXC: oxcarbazepine; PB: phenobarbital; PHT: phenytoin; RFN: rufinamide; TCA: tricyclic antidepressant; TGB: tiagabine; TPC: therapeutic plasma concentration; TPM: topiramate; VPA: valproic acid; ZNS: zonisamide.

<sup>a</sup> Not established.

<sup>b</sup> Compound: active ingredient and/or excipients contained in the specific preparation.

Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

**Table 11** AEDs in specific situations.

Clinical situation	Recommended drugs	Precaution	Contraindicated
<i>Pathological situations</i>			
Cardiopathies: heart failure and/or arrhythmia	Valproic acid Levetiracetam Gabapentin Lamotrigine Topiramate Pregabalin Tiagabine Zonisamide	Phenytoin Carbamazepine Oxcarbazepine Eslicarbazepine Lacosamide Retigabine	Phenytoin
Nephropathies, kidney failure, and/or haemodialysis	Valproic acid Lamotrigine Carbamazepine BZDs Phenytoin Tiagabine	Levetiracetam Topiramate Oxcarbazepine Eslicarbazepine Phenobarbital Zonisamide Lacosamide Retigabine	Vigabatrin Gabapentin Pregabalin
Liver diseases	Lacosamide Gabapentin Levetiracetam Oxcarbazepine Eslicarbazepine Pregabalin Topiramate	Carbamazepine Eslicarbazepine Ethosuximide Phenytoin Phenobarbital Primidone Zonisamide Retigabine	Valproic acid Clobazam Clonazepam Lamotrigine
HIV infection	Lacosamide Gabapentin Levetiracetam Eslicarbazepine Topiramate Zonisamide	Carbamazepine Lamotrigine Oxcarbazepine Phenytoin Phenobarbital Primidone	Valproic acid
Pneumopathies	Lacosamide Gabapentin Levetiracetam Lamotrigine Oxcarbazepine Eslicarbazepine Topiramate Valproic acid Zonisamide Retigabine	Carbamazepine Phenytoin	BZDs Phenobarbital Primidone
Cognitive impairment and/or learning disability	Lacosamide Gabapentin Levetiracetam Lamotrigine Eslicarbazepine Retigabine	Pregabalin Zonisamide Valproic acid Oxcarbazepine	BZDs Carbamazepine Phenobarbital Phenytoin Primidone Topiramate
Psychiatric disorders	Carbamazepine Oxcarbazepine Eslicarbazepine Lamotrigine Valproic acid BZDs	—	Phenytoin Phenobarbital Primidone Tiagabine Topiramate Levetiracetam
<i>Physiological situations</i>			
Pregnancy	Lamotrigine Carbamazepine	Topiramate Levetiracetam	All others
Oral contraception	Lacosamide Lamotrigine Levetiracetam Gabapentin Tiagabine BZDs	Valproic acid	Carbamazepine Phenobarbital Phenytoin Primidone Oxcarbazepine Topiramate
Old age	Lacosamide Levetiracetam Lamotrigine Gabapentin Zonisamide	All others (affect cognition)	—

Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.<sup>47,48</sup>

BZDs: benzodiazepines; HIV: human immunodeficiency virus.

**Table 12** Interactions between the most common antitumour and antiepileptic drugs.<sup>55,57,58,74</sup>

Antitumour	Antiepileptic	Interaction
AI (e.g., aminoglutethimide)	CBZ	↓ [AI]
	PHT	
	PB	
Capecitabine/5FU	PHT	↑ [PHT]
Carboplatin	PHT	↓ [PHT]
Cisplatin/doxorubicin	CBZ, PHT	↓ [CBZ], [PHT]
	PHT/VPA	↓ [VPA]/↑ [CDDP]
Taxanes (e.g., paclitaxel, docetaxel)	CBZ	↓ [Taxanes]
	PB	
	PHT	
TK inhibitors (–ab, –ib).	CBZ	↓ [TK inhibitors]
	PB	
	PHT	
Etoposide	CBZ	↓ [VP16]
	PB	
Tamoxifen	PHT/VPA	↓ [PHT]/↑ [VP16]
	CBZ	↓ [Tam], ↑ [PHT]
	PB	
Vinca alkaloids (e.g., vincristine)	PHT	
	CBZ	↓ [Vinca], [CBZ], [PHT]
	PB	
Methotrexate	PHT	
	CBZ	↓ [PHT], [CBZ], [PB] ↓ [Methotrexate]
	PB	
	VPA	↓ VPA
Nitrosoureas (e.g., BCNU, CCNU)	VPA	↑ [Nitrosoureas]
	CBZ	↓ [Nitrosoureas]
	OXC	
	PHT	
	PB	
	PMD	
	TPM	

AI: aromatase inhibitors; BCNU: carmustine; CBZ: carbamazepine; CCNU: lomustine; CDDP: cisplatin; PB: phenobarbital; PHT: phenytoin; PMD: primidone; TK: tyrosine kinase; Vinca: vinca alkaloids; VPA: valproic acid; VP16: etoposide; 5FU: 5-fluorouracil.

and/or sedatives may improve the well-being of patients and/or their families. (2) *Maintaining constant, effective communication with the patient and/or family* can be difficult. However, physicians should aim to ascertain the family's understanding of the disease and communicate as clearly as possible both with them and with the patient to facilitate subsequent joint decision-making. (3) *Supporting the family*: it is important to ensure that family members are informed and understand the patient's situation; families often refuse to accept the reality of the disease. Patients may also need other levels of care, such as psychiatric, social, neuropsychological, religious, and spiritual support. *General life support measures*.<sup>27,31,52</sup> Life support measures are taken from the onset of the seizure, and aim to stabilise the patient, prevent potential traumatic lesions, and control or prevent complications during and immediately after the seizure. The adapted protocol of the Advanced Trauma Life Support programme should be followed. The ABCDE mnemonic (airway, breathing/ventilation, circulation, disability, exposure and environment) comprises: (a) keeping the airway clear; (b) ensuring proper ventilation/

oxygenation; (c) ensuring good haemodynamic control: monitoring vital signs, inserting a peripheral venous catheter (preferably 2, one for extracting blood for analysis and another for administering serum therapy and drug treatment), and (where possible) correcting the primary cause (metabolic disorder, infection, etc.); (d) assessing level of consciousness, pupils (anisocoria > 1 mm is considered abnormal and may signal uncal herniation of the temporal lobe), and motor function; and (e) controlling exposure to prevent hypothermia.<sup>66</sup>

*Measures to improve patient well-being.* In PC, palliative sedation refers to the administration of drugs to decrease patients' level of consciousness in order to partially or completely reduce their perception of symptoms and/or signs causing unnecessary suffering due to their high severity or poor treatment response (refractory symptoms). Palliative sedation may be continuous or intermittent. In terminally ill patients, we refer to terminal sedation, which is administered continuously. The refractory symptoms most frequently leading to palliative sedation are delirium, agitation, dyspnoea, pain, anxiety, and first or recurrent



acute haemorrhage. Drug families of choice are benzodiazepines (BZDs: midazolam [MDZ] and diazepam [DZP]), opioids (morphine), neuroleptics (NLP), sedatives (chlorpromazine and levomepromazine), antipsychotics (haloperidol), barbiturates (PB), and anaesthetics (propofol). Specific drugs are selected according to symptoms, with delirium and agitation being treated with NLPs (first choice) or BZDs (second choice), especially MDZ; and dyspnoea, anxiety, and haemorrhage being treated with MDZ (first choice) or NLPs (second choice). Specific doses and administration guidelines are beyond the scope of this article; we recommend consulting articles, protocols, and CPGs on the subject.<sup>1,7,8,12,52,53</sup>

Treatment of peritumoural brain oedema and intracranial hypertension.<sup>1–159</sup> Treatment of recent-onset seizure aims to minimise the possibility of additional lesions. To that end, the patient's family should be trained to respond to a seizure.<sup>1</sup> Basic treatment of epileptic seizures is largely similar in palliative patients to in any other patient. AEDs should be selected according to seizure type, adverse reactions, and potential drug–drug interactions (with chemotherapeutic drugs, corticosteroids, etc.). If corticosteroids are administered, it may be necessary to monitor blood levels of many AEDs (especially dexamethasone [DXT] coadministered with PHT, as they reduce one another's levels via induction of the hepatic CYP450 enzyme system). Prophylactic corticosteroids are not indicated for seizures secondary to primary or metastatic brain tumours or brain radiation necrosis. This is also the case if there are no symptoms or signs of mild-to-moderate intracranial hypertension (headache, vomiting) or severe hypertension (intense vomiting and/or headache, altered level of consciousness, rapidly progressing neurological deficits) with stable neurological deficits. Cancer patients receiving AED treatment and displaying signs or symptoms of intracranial hypertension should be treated with corticosteroids (preferably DXT due to its reduced likelihood of causing salt retention and inhibition of leucocyte migration, and the resulting lower risk of superinfection, compared to other corticosteroids)<sup>59</sup> at 12 to 24 mg/24 hours for the shortest time possible (a 10-mg bolus may be administered intravenously as a loading dose, followed by a dose of 12 mg for signs and/or symptoms of mild-to-moderate intracranial hypertension, and 24 mg for severe intracranial hypertension, at intervals of 4, 6, or 8 hours, increasing the dose if there is no improvement within 48 hours and gradually reducing it by 4 mg every 48 hours if improvement is observed; the treatment may be withdrawn if no clinical response is observed within 48 hours of the 24-mg dose being administered), together with mannitol for the first 48 hours (1 mg/kg per 6–8 hours, maintaining plasma osmolality at 310–320 mOsm/kg). The patient's bed should be elevated > 30°, water intake should be restricted to < 1 to 1.5 L/day, and diuretic drugs should be administered (furosemide, 1 IV ampoule each 6–8 h).<sup>52,59,65</sup>

*Pharmacological treatment of acute symptomatic seizures.*<sup>27,31,52,90,91</sup> (a) Patients with brain tumours should not receive AEDs if they have not presented seizures (grade of recommendation: A).<sup>51</sup> (b) AED treatment should be started if the patient displays  $\geq 2$  unprovoked seizures, or one seizure with high likelihood of recurrence (e.g., focal seizure with a structural aetiology detected by neuroimaging or EEG) or in cases where the patient and/or

family are very concerned about the seizure. (c) Initial treatment should be monotherapy at low doses. (d) If seizures persist, the dose should be increased until seizure control is achieved or the maximum tolerable dose is reached. (e) In patients with poor seizure control, a different AED should be prescribed in addition to or in place of the first. (f) Blood AED levels should be used only as a guide; higher than normal AED levels should not prevent doses being increased if seizure control is poor. It is important to perform periodic monitoring to assess suboptimal levels. (g) AEDs should be selected according to the type of epilepsy and the adverse reactions associated with each drug. Second-generation AEDs with extrahepatic metabolism are recommended in patients with acute symptomatic seizures caused by brain tumours during radiotherapy, chemotherapy, or corticotherapy (recommendation of the Epilepsy Study Group of the Spanish Society of Neurology). (h) In patients with myoclonus (which all opioids may cause), it is necessary to investigate the cause; if it is treatable, it should be corrected or opioids rotated. If no cause is identified and/or the patient is terminal, BZDs should be administered (see first-line antiepileptic drugs section).

*Recommended antiepileptic drug treatment schedule for oncological patients.* Prophylactic AED administration is not recommended for patients with brain tumours as it does not reduce seizure incidence or increase seizure-free time, and increases the likelihood of adverse reactions. Prophylactic AED treatment is acceptable prior to surgery, but should be progressively withdrawn a week thereafter (level of evidence: 1).<sup>54,70–73,81</sup> The ideal drug will not interact with CYP450 isoenzymes and will show weak protein binding. New-generation AEDs have these qualities, although limited experience has been reported and many of these drugs are not without problems. LEV (20 mg/kg/day in 2 doses) is recommended as the first line of treatment and VPA (15 mg/kg/day in 3 doses) as the second-line AED.<sup>70</sup> There are a number of preliminary considerations to be taken into account for each drug.<sup>27–101,120–133</sup> OXC is a weak enzyme inducer. LMT often provokes skin toxicity, and dose up-titration is very slow. TPM may cause language problems, paraesthesia, and/or focal neurological signs; besides being a weak hepatic enzyme inducer, it can cause cachexia and a degree of metabolic acidosis. GBP is a weak AED requiring high doses, with a risk of CNS toxicity; the same is true of PGB, which also has a long up-titration period. Extensive evidence has been published on the use of VPA, a CYP450 inhibitor; the drug is highly effective in controlling seizures and presents significantly lower haematologic toxicity than would be expected, given its mechanism of action. VPA-induced hyperammonaemic encephalopathy is very rare. In addition to the increased haematologic toxicity associated with adjuvant treatment with temozolomide in patients with glioblastoma, longer survival times have been reported in comparison with patients not taking VPA,<sup>132</sup> as the drug has a degree of antineoplastic activity, attributed to inhibition of histone deacetylase activity and reduced protein kinase C activation. It is not recommended in patients receiving nitrosoureas (carmustine, lomustine); caution should also be exercised when coadministering with irinotecan. LEV has an optimal pharmacokinetic profile and is an effective alternative for treating seizures secondary to brain tumours. In vitro studies have also

found that it inhibits expression of O(6)-methylguanine-DNA methyltransferase (a DNA repair enzyme with an important role in tumour 'cells' resistance to alkylating agents and the cytostatic drug temozolomide).<sup>133</sup> Both VPA and LEV perform adequately in treating refractory epilepsy: LEV is not a substrate of P-glycoprotein (also known as multidrug resistance protein 1), and VPA inhibits its expression. A further advantage of both drugs is that they can be administered intravenously. In patients with refractory primary or metastatic brain tumours, coadministration of these drugs is recommended over sequential administration in monotherapy (achieving 81.5% responders, a 55.6% reduction in seizure frequency, 59% seizure-free patients, and an adequate safety profile).<sup>57,123</sup> Dose adjustment of such other new drugs as ZNS and LCM is a slow process; little evidence is available on their use to treat tumour-related epilepsy. ESL and RTG dose is adjusted quickly, although no evidence has been reported on their use in oncological patients.<sup>54</sup>

*Withdrawal of antiepileptic treatment in oncological patients following seizure remission.* Most authors recommend continuing AED treatment in adult patients with brain tumours and a history of seizures, given the risk of recurrence.<sup>57</sup>

*Treatment of convulsive status epilepticus.*<sup>12,27-40,107-114</sup> Treatment beginning within 60 minutes of SE onset is highly successful (80%); a delay of over 2 hours is associated with a 40%-50% success rate.<sup>12,34</sup> Depending upon the clinical context, IV DZP may be the first-line treatment. DZP (0.15-0.25 mg/kg) reaches the brain within seconds, although its antiepileptic effects are short-lasting; a second dose (maximum 20 mg) must therefore be administered 20-30 minutes later. DZP may be administered rectally in doses of 5 mg for children and 10 mg for adults. Intramuscular administration should be avoided due to the possibility of incorrect absorption. Another option is IV lorazepam (LZP) in a slow bolus (0.1-0.15 mg/kg over 1-2 min), which may be repeated after 5 minutes (this preparation is not available in Spain). A further option is MDZ, which can be administered subcutaneously. It is water-soluble, with onset of action of 3 minutes, 5 minutes, 10-15 minutes, and 15 minutes for IV, intramuscular, subcutaneous, and oral administration, respectively. For refractory cases, the initial dose is 0.2 mg/kg, followed by infusion at 0.05-0.5 mg/kg/hour. It is best to start at a dose of 1-2 mg in elderly patients. Rectal DZP and subcutaneous MDZ are particularly useful for treating seizures in dying patients. Patients with refractory seizures require emergency referral to the nearest reference hospital (given they are not terminally ill and/or the patient/family agrees to the referral) (see algorithm 1, Fig. 2).<sup>12,27-40</sup> Prognosis depends mainly on level of consciousness at SE onset; SE type, aetiology, and duration; and the patient's age. Stupor or coma at baseline predict poor neurological recovery; cerebral anoxia has the highest mortality rate (nearly 100%); generalised CSE or NCSE have poorer prognosis; and duration  $\geq$  60 minutes before onset of AED treatment, age  $\geq$  65, and absence of history of seizures are all associated with higher mortality rates.<sup>110-113</sup>

#### *First-line antiepileptic drugs*


- *Intravenous benzodiazepines:* LRZ and DZP are the drugs of choice, given the high level of evidence (1) and grade of recommendation for use in emergency departments.<sup>51</sup>

DZP has a faster onset of action than LRZ (1-3 vs 5 min), although its effect lasts a shorter time (10-30 min vs 12-24 h) as LRZ is less liposoluble and is not rapidly distributed into peripheral tissues, as is DZP, making it more effective.<sup>44</sup> No IV preparation is available in Spain. In addition to DZP, MDZ and CNZ are available in IV preparations. MDZ has a faster onset of action (1 min) and greater potency, but its half-life is very short; it therefore requires continuous perfusion, for which reason it is usually used only for controlling RSE. CNZ has a slower onset of action (3-10 min) and longer half-life (12 h), and is more often used for maintenance therapy.<sup>17-40,44</sup>

- *Alternative routes of administration for benzodiazepines:* MDZ is the drug of choice for intramuscular administration, showing similar efficacy to IV LZP as the initial prehospital treatment (level of evidence: 2).<sup>51</sup> In a randomised study of prehospital patients, Silbergleit et al.<sup>138</sup> found that MDZ (10 mg intramuscular) was at least as effective as LRZ (4 mg IV) in adults, particularly when venous access was not immediately achieved. However, it should be noted that metabolism by CYP450 3A4 enzymes may increase the likelihood of drug-drug interactions with DZP or LRZ.<sup>37</sup> Transmucosal administration (oral or nasal) has been shown to be effective in recent years, with a certain preference for this route. Transmucosal administration with oral solutions is accepted for use in paediatric patients (3 months to < 18 years). Non-IV (oral/nasal transmucosal, intramuscular, and rectal) MDZ is as effective as IV DZP; oral transmucosal MDZ is superior to rectal DZP (level of evidence: 2).<sup>5,27-40,44,51,84,97,99,101,102,139-143</sup> (a) *Rectal DZP* is the alternative to non-IV MDZ. Extensive evidence has been published on its use in both children (5-mg tube) and adults (10-mg tube). (b) *Subcutaneous CNZ* is a reasonable alternative in such settings as PC. (c) *LRZ via enteral route (oral, nasogastric tube, or percutaneous endoscopic gastrostomy)* may be a good option in PC.
- *Alternatives to benzodiazepines:* in cases of respiratory insufficiency or high risk of respiratory compromise due to sedation, or cases in which orotracheal intubation is not recommended, alternative treatment may be started with VPA (see dosage in section on SE) or IV lidocaine (bolus of 2 mg/kg in children and 100-200 mg in adults) (Table 13).<sup>27-40</sup>

*Second-line antiepileptic drugs.* The most recent guidelines recommend administering AEDs as early as possible; the latest trends follow this approach. Delayed onset of IV AEDs and/or administration at low doses is associated with poorer treatment response and prognosis. Seizures not resolving in the predetermined time with the measures described above are classified as SE. In these patients, treatment should be started with intravenous PHT, VPA, LEV, or LCM; no study with level of evidence 1 has shown any of these drugs to be superior. Therefore, the AED should be selected by exclusion according to comorbidities, tolerability, and potential drug-drug interactions; IV AEDs of choice in oncological patients are LEV, VPA, and LCM.<sup>44</sup> The following second-line AEDs are available (Table 13)<sup>27-40,44</sup>:

- *PHT*<sup>27-40,94-97</sup>: given the extensive published evidence and the US Food and Drug Administration recommendation, PHT is the second-line AED of choice for CSE in the



**Figure 2** Algorithm 1. Management of convulsive status epilepticus in patients receiving palliative care, particularly cancer patients. Other alternatives to anaesthetics: see Third-line antiepileptic drugs (induced coma) section. AED: antiepileptic drug; BIS: bispectral index; CSE: convulsive status epilepticus; EEG: electroencephalography; IM: intramuscular; IV: intravenous; LP: lumbar puncture; MV: mechanical ventilation; OTI: orotracheal intubation; PC; palliative care; SC: subcutaneous. Adapted with permission from the algorithm published by Fernández Alonso<sup>27</sup> in 2013 and modified for the context of palliative care based on the protocol of the Virginia Commonwealth University’s Thomas Palliative Care Unit (Richmond, Virginia, USA).<sup>139</sup>

majority of clinical guidelines. It is more effective in treating focal than generalised SE, and is not recommended for myoclonic or absence SE. PHT does not suppress respiratory function or impair consciousness. The drug’s greatest limitation is its cardiovascular toxicity (arterial hypertension, arrhythmias, etc); great caution should be exercised when prescribing it to elderly patients and/or those with heart disease. Due to its alkalinity (pH: 12)<sup>34</sup> it can also cause phlebitis; it should be administered via a different route than BZDs and should not be administered in sugar solutions. An additional disadvantage is that at the highest rate of administration, the necessary dose takes 30 minutes to be administered, which is too long to verify effectiveness and administer a second drug, where necessary, before considering anaesthesia as the third line of treatment. Due to potential interactions with antineoplastic drugs and the possible negative effects on lymphocyte function,<sup>94,95</sup> LEV is now recommended over PHT, with VPA and/or LCM to be added should that treatment be ineffective.<sup>27–40</sup>

- VPA: despite the absence of any study with level of evidence 1 on its use (only level 2B), many countries have approved use of the drug based on the cumulative evidence, published in over 300 studies,<sup>34</sup> that it is as

effective as PHT. Most guidelines recommend adding VPA if PHT is unsuccessful or contraindicated for patients with CSE. In a randomised, non-blinded study including 68 patients with CSE, high-dose VPA (30 mg/kg over 15 min) was more effective than PHT (18 mg/kg at 50 mg/min). In patients who were unresponsive to the first AED, VPA was more effective than PHT (79% vs 25% responders, respectively).<sup>144</sup> VPA has a series of advantages over PHT, including faster onset of action, better tolerability, mild sedation, absence of cardiotoxicity, and a broad spectrum of action. No adjustment needs to be made in patients with kidney failure; due to the high level of plasma protein binding, metabolism of the drug is not affected by dialysis. The most common adverse effects include hypotension, dizziness, and thrombocytopenia. In clinical practice, VPA has become established as an alternative to PHT in elderly patients and those with heart disease. The drug’s main limitation is its hepatic metabolism. It is contraindicated in patients with mitochondrial diseases, liver diseases, bleeding disorders, porphyria, immunosuppression, and HIV infection. Its use is not recommended in women of childbearing age as it can cause polycystic ovary syndrome and teratogenic effects.<sup>27–40</sup>

**Table 13** A. BZDs recommended for first-line treatment for CSE.<sup>19,27–39,96,138,139</sup> B. AEDs recommended for second-line treatment for CSE, administration schedule, and practical recommendations.<sup>19,23,27–40,136,137</sup> C. AEDs recommended for third-line treatment for CSE, administration schedule, and practical recommendations.<sup>22,23,27–40,134,135</sup> D. Treatment of NCSE.<sup>22,23,27,31,40–46,102</sup>

A. First-line AEDs for CSE	Route of administration	Initial loading dose and maximum dose	Observations
DZP	IV: 2 cc/10 mg ampoule diluted at 1 mg/mL	Adults: 5-20 mg (max. 2-5 mg/min) Children: 0.25-0.5 mg/kg	Administration in emergency departments (prehospital and at hospital) Administration after 2-5 min of seizures, typically 1-2 doses Preferably IV DZP, IM or transmucosal MDZ, or rectal DZP if IV unavailable
MDZ	Rectal: 5- or 10-mg microenema	Adults: 10-30 mg (max. 5 mg/min) Children: 0.5-0.75 mg/kg	
	Bucchal, intranasal, IM, or SC (especially indicated in dying patients) (5-, 15-, or 50-mg ampoule)	Adults: 5-30 mg (max. 5 mg/min) Children: 0.15-0.3 mg/kg	
CNZ	IV or SC (1-mg/1-mL ampoule)	Adults: 1-30 mg (max. 0.2 mg/min) Children: 0.2-0.5 mg	
(B) Second-line AEDs for CSE	Administration schedule		Practical recommendations
	Initial dose	Maintenance dose	
PHT (100- or 250-mg ampoule)	15-20 mg/kg at 20-50 mg/min E.g., 1 g in 250 cc 0.9% saline over 30 min	1-2 mg/kg/8 h (12 h after initial dose) E.g., 100 mg/8 h, IV administration	AEDs of choice for young adults with no comorbidities (cardiovascular) in a stable condition
VPA (400-mg ampoule)	15-30 mg/kg (4–6 mg/kg/min) E.g., 1.2 g diluted/undiluted over 5-15 min	0.5-1 mg/kg/h (0.5 h after initial dose) E.g., 800 mg/24 h	Alternative treatment if PHT is contraindicated or insufficient in patients without liver disease
LEV (500-mg ampoule)	20 mg/kg (250-3000 mg) over 15 min or 2-5 mg/kg/min in 100 cc 0.9% saline E.g., 1 g over 15 min or 500 mg over 5 min (3×)	20-30 mg/kg/24 h (12 h after initial dose) max. 3000 mg/day E.g., 500-1500/12 h in 100 cc 0.9% saline	Alternative treatment in elderly patients or patients with heart or liver comorbidities and/or lack of response to PHT and/or VPA
LCM (200-mg ampoule)	100-400 mg over 3-15 min E.g., 200 mg undiluted over 5 min	100-200 mg undiluted (12 h after initial dose)	Optional AEDs if no response to previous AEDs (PHT, VPA, and LEV)
(C) Third-line AEDs for CSE	Administration schedule		Practical recommendations
	Initial dose	Maintenance dose	
<i>Coma (non-barbiturates)</i>			
MDZ (5-, 15-, or 50-mg ampoule)	0.2-0.3 mg/kg bolus (2 mg/min)	0.05-2 mg/kg/h	Preferable in haemodynamically unstable patients
PPF (10- or 20-mg ampoule)	1-2-mg/kg bolus (20 µg/kg/min)	5-10 mg/kg/h (dangerous if > 80 µg/kg/min)	Infusion syndrome, contraindicated in patients aged < 16, requires OTI + MV

Table 13 (Continued)

Coma (barbiturates)			
PB (200-mg ampoule)	5-20 mg/kg over 20-30 min (20-50 mg/min)	2–4 mg/kg/day; 0.1-5 mg/kg/h (12-24 h after initial dose)	Alternative to non-barbiturates: greater efficacy and fewer adverse reactions Requires OTI + MV
TPT (500-mg ampoule)	2-7 mg/kg; 100-200 mg over 1 min 50 mg/2–5 min until seizure control achieved	(1-5 mg/kg/h)  (0.05-2 mg/kg/h)	
(D) NCSE	Treatment of choice	Other options	
Typical absence	BZD (IV or transmucosal; SC administration should be considered in oncological patients)	VPA LEV	
Atypical absence	IV DZP VPA/LEV, IV or oral	LTG TPM	
Partial complex	DZP + PHT PB	CLB LEV (treatment of choice in oncological patients)	
Subtle NCSE (patient in coma)	PB	MDZ (treatment of choice in oncological patients) TPT PPF	

AED: antiepileptic drug; BZD: benzodiazepine; CLB: clobazam; CNZ: clonazepam; DZP: diazepam; IM: intramuscular; IV: intravenous; LCM: lacosamide; LEV: levetiracetam; LTG: lamotrigine; MDZ: midazolam; MV: mechanical ventilation; OTI: orotracheal intubation; PB: phenobarbital; PHT: phenytoin; PPF: propofol; SC: subcutaneous; TPM: topiramate; TPT: thiopental; VPA: valproic acid.

A, B, C: adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

D: adapted with permission from Mercadé-Cerdá et al.,<sup>23</sup> 2013.

- LEV is one of the newest alternatives to PHT and VPA when these drugs are contraindicated or ineffective. It became available for IV administration in 2007, so published experience is more limited. The main evidence is from case series of patients with CSE or NCSE treated with LEV as the first second-line AED, or after PHT or VPA. Effective dose is 500-3000 mg/day, with seizure control achieved 12-96 hours after administration. Up to 1500 mg/minute is tolerable. A safe and effective rate of administration is 500 mg every 5 minutes for 15 minutes. No sufficiently well-designed study compares LEV to PHT and VPA. In a 2011 study, Alvarez et al.<sup>145</sup> performed an analysis adjusted for SE aetiology and severity and found that PHT was more effective than LEV and less effective than VPA. Various studies have reported similar effectiveness for LEV and VPA at 30 minutes for treating CSE and absence NCSE.<sup>146–148</sup> The drug's main advantages are its safety, absence of severe adverse reactions, few drug–drug interactions, linear pharmacokinetics, and ease of administration. Due to its metabolism, dose should be reduced by half in patients with creatinine clearance below 30 mL/minute. LEV is a good option as the first AED in elderly, oncological, or polymedicated patients, or patients with cardiovascular or liver comorbidities, and constitutes a good alternative if PHT or VPA are ineffective.<sup>27</sup> LEV has also been observed to have an antiemetic effect, although the specific mechanism of action involved is unclear.<sup>125</sup> Finally, a

2014 literature review and a recent case report have observed a good balance between efficacy and safety for subcutaneous administration of LEV as an alternative route of administration in PC.<sup>149,150</sup>

- LCM, available in Spain since 2011, is the newest AED to be used in SE, and was initially developed for IV administration. It is a new treatment option for situations where SE is unresponsive to the drugs discussed above, particularly for focal CSE, although good results have also been reported for generalised CSE. The level of evidence and grade of recommendation are limited (3D). Nineteen articles (10 clinical cases and 9 case series) have been published, including 136 patients (50% CSE: 31% focal and 19% generalised CSE) aged between 8 and 90, treated with LCM after lack of response to other AEDs; LCM was successful in nearly 60% of patients, particularly when combined with VPA and/or LEV. Efficacy appears to improve with earlier administration of the drug. Dosage typically ranges between 100-400 mg over 3-15 minutes. A dose of 200-300 mg over 15 minutes showed similar efficacy to a 400-mg dose, but greater safety. The 400-mg dose, in turn, was safer than a 600-mg dose (not indicated in the summary of product characteristics), with fewer adverse reactions. LCM has a good safety profile, with no severe adverse reactions, with the exception of one case of complete heart block associated with class I antiarrhythmics (sodium channel blockers). The most frequent adverse reactions are mild, dose-dependent neurological



alterations. Like LEV, LCM has a profile similar to that considered ideal in emergency departments, with optimal potential for treating SE.<sup>27–40</sup>

- **PB:** barbiturates were the first drugs to be used regularly to treat SE; from the early 20th century until the arrival of BZDs in the 1960s, they were first-line AEDs. PB continues to be the second most frequently used AED after BZDs in developing countries, with comparable efficacy to PHT. In Spain, it is indicated as an alternative to PHT in SE. It continues to be a good option for neonatal seizures. The main limitation is the drug's poor safety profile: it is associated with a risk of haemodynamic instability and a need for mechanical ventilation, as well as cognitive and behavioural alterations. With the introduction of the new IV AEDs, its use as a second-line AED has fallen; it is now used as a third-line drug to induce coma (Table 12).<sup>27–40</sup>

According to the available evidence on established CSE, intravenous DZP + PHT, PB, and LZP are equally effective for controlling CSE at 20 minutes after perfusion onset and during the first hour (level of evidence: 1).<sup>51</sup> Intravenous PHT and VPA, and VPA and LEV are equally effective for controlling CSE at 30 minutes after perfusion onset and in patients with adverse reactions (level of evidence: 2).<sup>51</sup> Intravenous LCM has been shown to be effective in various non-prospective, non-controlled studies and case series for different types of CSE (level of evidence: 4).<sup>51</sup> Most CPGs recommend LZP (4 mg IV) or DZP (10 mg IV), followed by PHT (18 mg/kg IV) or PB (20 mg/kg IV) (level of evidence: 4).<sup>51</sup> Treatment with VPA, LEV, or LCM is indicated in cases of RSE or when PHT is contraindicated, as an alternative to IV PB (level of evidence: 3).<sup>51</sup> LEV plus LCM is not indicated for treating SE.<sup>51</sup> According to grade of recommendation, BZDs should be used for the initial pharmacological treatment of any prolonged seizure or SE episode (grade of recommendation: A). Intravenous PHT and/or PB should be used if SE is not controlled with BZDs (grade of recommendation: A). SE should be treated with IV VPA and/or LEV if PHT is contraindicated (grade of recommendation: B). LEV and LCM may be used to treat SE if PHT is contraindicated, as an alternative to IV PB, or in RSE (grade of recommendation: C). In PC of oncological patients, second-line treatments (to be administered for no longer than 30 minutes after CSE onset) should be, in order of choice: LEV, LEV + VPA, LEV + LCM, VPA + LCM, and LEV + VPA + LCM.<sup>27–40</sup> PMP via nasogastric tube has been tested in several small case series (the largest including 12 patients), which are too heterogeneous to allow reliable conclusions to be drawn regarding its efficacy in treating CSE.<sup>44</sup> BRV is available in an IV preparation; although epilepsy experts consider it to be a potential adjuvant AED for treatment of SE, no studies have yet been published on its use in humans.<sup>44</sup>

#### *Third-line antiepileptic drugs (induced coma).*<sup>27–40,139,140</sup>

If after 30 minutes SE does not respond to treatment with second-line AEDs, anaesthetics should be considered (provided that the patient does not meet criteria for terminal illness and the patient and/or family consents). One limitation of these drugs is their systemic effects (arterial hypotension, myocardial depression, and hepatotoxicity). Anaesthetics should be administered in ICUs; patients should be monitored via ECG and EEG and receive life support. If

otracheal intubation is required, muscle relaxants with short half-lives, such as vecuronium, are preferred as they do not interfere with subsequent neurological assessment. Selection of drugs used to induce medical coma for RSE should be based on the experience and/or protocols of the ICU. ICU admission is ideally avoided in cancer patients receiving PC.<sup>102</sup> There are 2 means of inducing coma: barbiturates and non-barbiturates. No sufficiently high-quality studies have shown that either type of drug is superior to the other (level of evidence: 4).<sup>27–40,44,51</sup>

- *Coma induced with non-barbiturates (MDZ/propofol):* these drugs are preferred over barbiturates in haemodynamically unstable patients due to their greater safety and faster onset of action. MDZ and propofol are the most commonly used drugs. MDZ has the better safety profile; it should be noted that adverse reactions and tachyphylaxis are more common if constant infusion is used.<sup>39,139</sup> While propofol is safe at low doses, there is a risk of potentially fatal propofol infusion syndrome (severe metabolic acidosis, rhabdomyolysis, kidney failure, arterial hypotension, apnoea, bradycardia, etc). Vital signs must be monitored for this reason; the drug is contraindicated in children.<sup>17–40,139–143</sup>
- *Coma induced with barbiturates (PB/thiopental):* barbiturates are only used as a rescue drug when non-barbiturates fail, and should be avoided in haemodynamically unstable patients due to the associated adverse reactions (especially hypotension and sedation). Efficacy is comparable to that of PHT. No clear differences have been observed between PB and thiopental (which is converted to its active metabolite pentobarbital) with the exception of the latter's cardiovascular toxicity (Table 13).<sup>151</sup>
- *Alternatives to anaesthetics:* inhaled anaesthetics (isoflurane, desflurane); IV lidocaine; IV ketamine; IV magnesium sulphate (especially in women with eclampsia); AEDs (enteral TPM; oral CBZ or CLB); immunotherapy (corticosteroids and/or immunosuppressors); and non-drug treatments (ketogenic diet, therapeutic hypothermia, or vagus nerve stimulation), among other treatments.<sup>27–40,44,47,81,83,89</sup>

*Treatment of nonconvulsive status epilepticus.* No guidelines or expert consensus documents on treatment of NCSE are currently available due to a lack of studies and efficacy data. The recommendations are the same as those for CSE, but with a lower level of evidence (recommendation of the Epilepsy Study Group of the Spanish Society of Neurology).<sup>51</sup> Aggressive approaches are not recommended for patients who are not in deep coma, as the consequences are less severe. It is therefore recommended to start treatment with BZDs and monitor the response. Should epileptic activity continue, second-line AEDs should be administered: VPA and LEV are preferred for absence SE and LEV and PHT are recommended for partial complex SE. Due to its efficacy, safety, and broad spectrum of action, LCM seems to be a good option for refractory cases (Table 13).<sup>27,40,41</sup>

#### *Summary of treatment for convulsive status epilepticus (Fig. 2)*<sup>1–151</sup>

*Preventive antiepileptic treatment after the first seizure*<sup>27</sup>

**Table 14** A. Summary of the main indications for AEDs for secondary prevention. B. AEDs as preventive treatment.


(A) Indications for starting secondary seizure prevention	Duration of secondary prevention
<b>Second unprovoked seizure or SE</b>	<b>Long-term</b>
<b>First seizure and high risk of recurrence</b>	Short-term (introduction in acute phase)
<i>Acute symptomatic seizure if:</i>	* Primary prevention (1 week)
– Acute structural alteration (CNS infection, stroke, severe head trauma*)	
– Alcohol withdrawal	
– Eclampsia	
<i>Remote symptomatic seizure: all Seizure of undetermined aetiology</i>	Long-term (assess starting administration during acute phase, prior to discharge from emergency department; await specialist neurology consultation)
– Not GTC at onset	
– Neurological deficit	
– Very young or old patient	
– Focal neurological signs following seizure (e.g., Todd paralysis)	
– Lesion visible on neuroimaging scans	
– Epileptiform activity on EEG	
(B) AEDs as preventive treatment	Observations
<b>Recommendations during acute phase (order of preference)</b>	IV administration recommended during acute phase
1. LEV	
2. VPA	
3. PHT	
4. CBZ (oral)	
<b>After acute phase, secondary prevention with LEV</b>	Upon discharge from the emergency department, treatment should continue with oral administration, if possible.
<i>Alternatives</i>	
LTG	
VPA	
OXC	

AED: antiepileptic drug; CBZ: carbamazepine; CNS: central nervous system; EEG: electroencephalography; GTC: generalised tonic clonic; IV: intravenous; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PHT: phenytoin; SE: status epilepticus; VPA: valproic acid. Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

- *Initial AEDs for preventive treatment:* the first course of action is to decide whether secondary preventive treatment in the acute phase should be applied in the short term, to prevent early recurrence, or maintained in the long term (difficult to determine during the acute phase). The AED treatment strategy must ensure greater benefits than risks to the patient and must be agreed with the patient and family, taking into account their preferences.
- *Risks and benefits related to the initial AED:* the introduction of AED treatment should aim to minimise the risk of recurrences, as additional seizures are associated with increased risk of accidents, work restrictions, social stigma, and even sudden death, as well as repeated emergency department visits. Patients presenting SE or a second unprovoked seizure have a greater risk of recurrence (70% in the first year). Patients only experiencing one stroke are at less risk (40% at 2 years). AED treatment after a first seizure reduces the risk of recurrence to a mean of 34%, especially in the short term (< 2 years). However, no clear differences have been observed in the long term (> 5 years); nor does vital prognosis significantly improve (level of evidence: 1).<sup>27,51</sup>

A series of risk factors have been described for seizure recurrence: seizure type (focal onset, symptomatic aetiology), number of seizures ( $\geq 2$ ), abnormalities detected in neurological examination, epileptiform activity on EEG, and structural alteration on neuroimaging scans. The Multicentre Trial for Early Epilepsy and Single Seizures established a prognostic index for seizure recurrence, based on these factors: *a)* one point if the patient experienced 2 or 3 seizures prior to consultation, and 2 points for 4 or more seizures; and *b)* one additional point if the patient displays neurological disorder, learning disorder, or developmental delay, and a further point for EEG abnormalities (epileptiform activity or slow waves). Risk is classified as low (0 points), medium (1 point), or high (2-4 points).<sup>152</sup>

- *Indications for preventive treatment (Table 14)*<sup>27</sup>: treatment is generally recommended following SE,  $\geq 2$  unprovoked seizures, or one seizure (provoked or not) accompanied by EEG alterations, some potentially epileptogenic neurological disorder (acute structural alteration and/or previous disease), or great psychosocial demand on the part of the patient. AED treatment should be started in



**Figure 3** Algorithm 2. Treatment adjustment for decompensation. AED: antiepileptic drug. Adapted with permission from Fernández Alonso et al.<sup>27</sup>

patients at medium or high risk ( $\geq 1$  point). In any case, patients should be referred to a neurology consultation (epilepsy unit) in order to complete the aetiological study and to start or continue long-term antiepileptic treatment.

- *Selection of AEDs for preventive treatment* (Table 14)<sup>27</sup>: drug choice should be based on seizure type (classification), patient characteristics (age, comorbidities, and other treatments), and drug characteristics (efficacy, safety, availability, and ease of use).

*Adjustment of antiepileptic drugs in cases of decompensation* (Algorithm 2, Fig. 3)<sup>27</sup> Decompensation may occur in various clinical scenarios; safety is the primary concern in all cases. Patients should be referred to hospital if they present specific risk factors: suspicion of a new cerebral lesion (different seizure characteristics, abnormal neurological examination, and/or underlying disease such as cancer, AIDS, etc), prolonged or recurrent seizures (SE or cluster seizures [ $\geq 3$  seizures in 24 h), and/or suspected systemic and/or traumatic complications. Pragmatically, we can distinguish between decompensation related to seizure recurrence (efficacy) and decompensation associated with adverse drug reactions (safety) (Fig. 3).

- *Recurrent seizures*: (a) *similar to typical seizures*: patients with no change in seizure type or frequency. A conservative approach should be taken with these patients, with normal follow-up (complementary testing

is unnecessary), maintaining or restarting the habitual treatment, and stressing the importance of avoiding triggers and ensuring treatment adherence. (b) *Increased seizure frequency*: it is important to consider proper treatment adherence and whether AED levels are within the therapeutic range. Tests should be performed to determine levels of PHT (10-20  $\mu\text{g}/\text{mL}$ ), PB (10-40  $\mu\text{g}/\text{mL}$ ), CBZ (4-12  $\mu\text{g}/\text{mL}$ ), and VPA (50-100  $\mu\text{g}/\text{mL}$ ). If the trigger factor is clearly treatment withdrawal or non-adherence and seizures were controlled when the patient was using the drugs, treatment should be restarted. In cases where adherence is thought to be good and AEDs are detected at subtherapeutic levels, drug-drug interactions and/or intercurrent disease should be suspected. In these cases, we should increase the AED dose or consider changing to another drug without these interactions. If AED levels do fall within the therapeutic range, we can increase the dose and/or add other AEDs. If the maximum dose for the drug in question is prescribed and levels of the drug are unknown, we may add a new AED or await the next neurology consultation.
- *Adverse reactions to AEDs*<sup>27,45</sup>: (a) *pharmacological adverse reactions (dose-dependent)*: most effects involve the CNS (drowsiness, ataxia, dysarthria, diplopia, blurred vision, etc.). This is managed by reducing the dose and the speed of up-titration. Monitoring AED levels is useful if they are below the therapeutic range; in this way we can identify a parallel between clinical improvement and normalisation of AED levels. (B) *Idiosyncratic adverse reactions (dose-independent)*: mild adverse

**Table 15** Most frequently administered brand-name AEDs for oral administration (where possible) and dosing information.

Oral AED (mg)	Initial dose	Up-titration	Mean maximum dose
<i>1st generation</i>			
Phenytoin, Sinergina <sup>®</sup> (100)	100 mg every 8-12 h	50-100 mg/day every week	200-600 mg/day (2–3 doses)
Carbamazepine, Tegretol <sup>®</sup> (200, 400)	100-200 mg every 12-24 h	100 mg/day every week	600-1600 mg/day (3 doses)
VPA, Depakine <sup>®</sup> (200, 500, Crono 300, Crono 500)	200 mg every 8 h	200 mg/day every 3 days	1000-3000 mg/day (2–3 doses or 1-2 doses Crono)
<i>2nd generation</i>			
Lamotrigine, Lamictal <sup>®</sup> (25, 50, 100, 200)	25 mg every 24 h	(A) 50 mg/day every 1-2 weeks (monotherapy and coadministration with enzyme inducers) (B) 25 mg/day every 1-2 weeks (coadministration with VPA)	100-500 mg/day (2 doses)
Topiramate, Topamax <sup>®</sup> (25, 50, 100, 200)	25-50 mg every 24 h	25-50 mg/day every week	200-800 mg/day (2 doses)
Gabapentin, Neurontin <sup>®</sup> (100, 300, 400, 600, 800)	300-400 mg every 24 h (day 1)/12 h (day 2)/8 h (day 3)	300-400 mg/day every 1-3 days	900-3600 mg/day (2-3 doses)
Oxcarbazepine, Trileptal <sup>®</sup> (150, 300, 600)	150-300 mg every 12 h	600 mg/day every week	600-2400 mg/day (2 doses)
Levetiracetam, Keppra <sup>®</sup> (250, 500, 1000)	250-500 mg every 12 h	500-1000 mg/day every week	1000-3000 mg/day (2 doses)
Zonisamide, Zonegran <sup>®</sup> (25, 50, 100)	25-50 mg every 24 h	50-100 mg/day every week	100-500 mg/day (2 doses)
<i>3rd generation</i>			
Lacosamide, Vimpat <sup>®</sup> (50, 100, 150, 200) <sup>a</sup>	50 mg every 12 h	100 mg/day every week	200-400 mg/day (2 doses)
Eslicarbazepine, Zebinix <sup>®</sup> (800)	400 mg every 24 h	400 mg/day every 1-2 weeks	400-1200 mg/day (1 dose)
Retigabine, Trobalt <sup>®</sup> (50, 100, 200, 400)	100 mg every 8 h	100-150 mg/day every week	600-1200 mg/day (3 doses)
Rufinamide, Inovelon <sup>®</sup> (100, 200, 400)	100-400 mg every 24 h	200-400 mg/day every 2 days	1200-4800 mg/day (2 doses)
Perampanel, Fycompa <sup>®</sup> (2, 4, 6, 8, 10, 12)	2 mg every 24 h	2 mg/day every week	6-12 mg/day (1 dose)
Brivaracetam, Briviact <sup>®</sup> (10, 25, 50, 75, 100)	25 mg every 12 h	Not necessary (therapeutic dose is reached on day 1)	50-200 mg/day (2 doses)

VPA: valproic acid.<sup>27,45,46,154–158</sup><sup>a</sup> Loading dose: 200 mg over 15 min (oral or intravenous). Maintenance dose: 200 mg/day (2 doses), 12 h after the loading dose.Adapted with permission from Fernández Alonso et al.,<sup>27</sup> 2013.

reactions (particularly skin rashes) are relatively frequent, although more severe reactions can affect the skin (Stevens–Johnson syndrome), bone marrow (agranulocytosis), or liver (toxic hepatitis). Hypersensitivity reactions (fever, exanthema, adenopathy, oedema, etc) can be very severe, and appear more frequently in association with CBZ, PHT, PB, LTG, OXC, and ZNS. In patients with exanthema, the AED should be changed for one with lower risk, such as LEV, GBP, or TPM. Cognitive adverse effects are frequent in elderly patients, especially in association with classic AEDs. VPA is contraindicated in women of childbearing age due to its effects on the reproductive organs and foetus. Hyponatraemia is an issue frequently associated with CBZ and derivatives (OXC and ESL) and often leads to changes or withdrawal of AEDs.

Regarding rational polytherapy for refractory epilepsy (which is frequent in oncological patients), most authors recommend trying the new AEDs if seizure control is not achieved and the drugs are indicated. LCM is a good option in these situations as it features a novel mechanism of action and a near-ideal clinical profile. Current evidence is limited, as it comes from non-randomised, open-label trials, case series, post hoc analyses, and expert opinions. The following are considered “potentially useful combinations”: non-sodium channel blocking AEDs (e.g., VPA or LEV)+LCM; LCM or VPA+LEV, TPM, ZNS, or LCM; CBZ, OXC, ESL, or PHT+LEV, LCM, ZNS, or RTG; and VPA+ESM. Caution is necessary when administering CBZ, OXC, ESL, or PHT+LTG; VPA+PHT; or CBZ or PHT+TPM or TGB. The following combinations are not recommended: CBZ+PHT; and OXC+ESL, PRM, TGB, or VGB. Finally, changing brand-name for generic AEDs is not recommended in patients who are seizure-free or have refractory epilepsy.<sup>27,153</sup> Table 15 lists the most commonly used brand-name oral AEDs.

## Conclusions

Given the relative frequency of seizures in PC and the creation of the new PC unit being opened at our neurorehabilitation centre, we deemed it necessary to produce these guidelines. In addition to informing the proper selection of candidates for PC, it is essential to achieving optimal symptomatic control of seizures and preventing distress, suffering, and pain for these patients and their families. This enables us to provide a standard of well-being and comfort in the final stage of life. Based on the findings of a thorough literature search and the needs of these patients, we recommend using AEDs via parenteral route (preferably IV) and selecting drugs with few interactions. DZP and MDZ are the most appropriate drugs in the acute stage; LEV, VPA, and/or LCM should be used for long-term treatment or for epilepsy refractory to DZP or MDZ, where more effective symptomatic treatment is needed. These guidelines should be considered a global approach and should be adapted holistically, from a multidisciplinary perspective, according to the inherent characteristics of each individual case, observing the wishes and priorities of the patient/family. No

national consensus document has yet been published on this subject. There is a need for well-designed, randomised, controlled trials with large samples of patients receiving PC. This would enable such a national document to establish well-founded, generalised recommendations on appropriate, rational, and effective use of AEDs in this highly delicate, complex area of healthcare.

## Limitations

We include a table clarifying the levels of evidence and grades of recommendation for the different treatments discussed. This information is needed for all treatments, as the main issue in the preparation of these guidelines is the lack of published evidence. This will be addressed in future updates of this initial version of the CPG as new studies are published on the subject.

## Funding

This study received no public or private funding.

## Conflicts of interest

All authors have given their approval for the publication of the manuscript. The authors have no conflicts of interest to declare.

## Acknowledgements

We wish to thank all the patients and employees of San Vicente Clinic.

## References

1. Grupo de Trabajo de la Guía de Práctica Clínica sobre Cuidados Paliativos. Guía de Práctica Clínica sobre Cuidados Paliativos. Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco; 2008. Guías de Práctica Clínica en el SNS: OSTEBA N° 2006/08 [accessed 17.01.16]. Available from: [http://www.guiasalud.es/GPC/GPC\\_428\\_Paliativos\\_Osteba\\_compl.pdf](http://www.guiasalud.es/GPC/GPC_428_Paliativos_Osteba_compl.pdf)
2. Koekkoek JA, Chang S, Taphoorn MJ. Palliative care at the end-of-life in glioma patients. *Handb Clin Neurol*. 2016;134:315–26.
3. Wrede-Seaman LD. Management of emergent conditions in palliative care. *Prim Care*. 2001;28:317–28.
4. Callahan D. Death and the research imperative. *N Engl J Med*. 2000;342:654–6.
5. Pace A, Metro G, Fabi A. Supportive care in neurooncology. *Curr Opin Oncol*. 2010;22:621–6.
6. Sanz Fernández ME, Molinero Blanco E. Cuidados paliativos en el paciente oncológico. *Medicine*. 2013;11:1669–76.
7. Casal Codesido JR, Carnero López B. Manejo básico del paciente con urgencia oncológica. In: Fernández Fernández G, editor. Guía de urgencias oncológicas; 2014. p. 9-



- 15 [accessed 17.01.16]. Available from: <https://drive.google.com/file/d/0B7LpU5xHwFp1LVFQT0hwdUt350k/view>
8. Definiciones. In: Agustín Illueca MP, Arrieta Canales J, Benites Burgos A, del Río García ML, Moral Lamela AI, Rodríguez Franco E, et al., editors. Manual para el manejo del paciente en cuidados paliativos en urgencias extrahospitalarias. Barcelona: Editores 2011-SUMMA 112; 2011. p. 9-12 [accessed 17.01.16]. Available from: <http://www.paliativossinfronteras.com/upload/publica/Manualurgencias-cuidados-paliativos.1.pdf>
  9. Moore G, Collins A, Brand C, Gold M, Lethborg C, Murphy M, et al. Palliative and supportive care needs of patients with high-grade glioma and their carers: a systematic review of qualitative literature. *Patient Educ Couns*. 2013;91:141–53.
  10. Sauro KM, Wiebe S, Dunkley C, Janszky J, Kumlien E, Moshé S, et al. The current state of epilepsy guidelines: a systematic review. *Epilepsia*. 2016;57:13–23.
  11. Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. *Eur J Neurol*. 2004;11:577–81.
  12. Díaz-Albo Hermida E, Astudillo A W. Manejo de situaciones urgentes en cuidados paliativos [accessed 17.01.16]. Available from: <http://www.paliativossinfronteras.com/upload/publica/libros/cuidados-pal-labor-todos/05-MANEJO-DE-SINTOMAS-URGENTES-EN-CUIDADOS-PALIATIVOS-DIAZ-ALBO.pdf>
  13. Núñez Olarte JM. Revisión de los criterios técnicos y éticos de la sedación en Cuidados Paliativos. Unidad de Cuidados Paliativos. Hospital General Universitario Gregorio Marañón; 2011, octubre 21; Madrid, XVIII Congreso Nacional de Derecho Sanitario [accessed 17.01.16]. Available from: <http://www.aeds.org/congreso/XVIIIcongreso/ponencias/JMNunezOlarte.pdf>
  14. García Barragán N, Rodríguez Osorio X. Tratamiento. Tratamiento farmacológico. Epilepsia refractaria o farmacoresistente. In: Martínez Castrillo JC, editor. *Neurolinks en epilepsia*. Las Rozas: Adalia farma, S.L.; 2012. p. 173.
  15. Villanueva Haba V, Donaire Pedraza AJ. Epilepsia refractaria a fármacos antiepilépticos. Politerapia racional. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012*. 1. Guía oficial de práctica clínica en epilepsia. Madrid: LUZÁN 5, S.A.; 2012. p. 185–93.
  16. García Barragán N, Toledano Delgado R, Falip Centellas M, Vivanco Hidalgo R. Clínica. Semiología. Tipos de crisis. In: Martínez Castrillo JC, editor. *Neurolinks en epilepsia*. Las Rozas: Adalia farma, S.L.; 2012. p. 15–29.
  17. Saiz Díaz RA, Sancho Rieger J. Terminología de las crisis epilépticas y epilepsia. Semiología de las crisis epilépticas. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012*. 1. Guía oficial de práctica clínica en epilepsia. Madrid: LUZÁN 5, S.A.; 2012. p. 17–28.
  18. Serrano Castro P, García Martín G. Utilidades. Clasificaciones. ILAE. In: Martínez Castrillo JC, editor. *Neurolinks en epilepsia*. Las Rozas: Adalia farma, S.L.; 2012. p. 239–53.
  19. García Morales I. Estado epiléptico. Estado epiléptico. In: Martínez Castrillo JC, editor. *Neurolinks en epilepsia*. Las Rozas: Adalia farma, S.L.; 2012. p. 229–37.
  20. García Barragán N, Toledano Delgado R, Falip Centellas M, Vivanco Hidalgo R. Clínica. Semiología. Imitadores de epilepsia. In: Martínez Castrillo JC, editor. *Neurolinks en epilepsia*. Las Rozas: Adalia farma, S.L.; 2012. p. 45–51.
  21. Casas Fernández C, Serrano Castro PJ. La historia clínica en epilepsia. Diagnóstico diferencial de la epilepsia en las distintas edades. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012*. 1. Guía oficial de práctica clínica en epilepsia. Madrid: LUZÁN 5, S.A.; 2012. p. 29–38.
  22. Serrano-Castro PJ, Sánchez-Álvarez JC, Cañadillas-Hidalgo FM, Galán-Barranco JM, Moreno-Alegre V, Mercadé-Cerdá JM. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia. *Rev Neurol*. 2009;48:39–50.
  23. Mercadé-Cerdá JM, Sánchez-Álvarez JC, Galán-Barranco JM, Moreno-Alegre V, Serrano-Castro PJ, Cañadillas-Hidalgo FM. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico. *Rev Neurol*. 2009;48:489–95.
  24. Mercadé-Cerdá JM, Gascón-Jiménez FJ, Ramos-Lizana J, Sánchez-Álvarez JC, Serrano-Castro PJ. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis. *Rev Neurol*. 2009;49:270–6.
  25. Juárez Belaúnde AL, Cabeza Álvarez CI, Garrido Robres JA. Crisis comiciales y estatus epiléptico. In: Julián Jiménez A, editor. *Manual de protocolos y actuación en Urgencias*. 4.ª ed. Madrid: Sanidad y Ediciones, S.L. (SANED); 2014. p. 579–92.
  26. Zurita Santamaría J, Maestro de la Calle G. Crisis comiciales. In: Aguilar Rodríguez F, Bisbal Pardo O, Gómez Cuervo C, de Lagarde Sebastián M, Maestro de la Calle G, Pérez-Jacoiste Asín MA, et al., editors. *Manual de diagnóstico y terapéutica médica*. Hospital Universitario 12 de Octubre. 7.ª ed. Madrid: MSD; 2013. p. 1225–38.
  27. Fernández Alonso C. Monografías de emergencias. Actualización: tratamiento de las crisis epilépticas en urgencias. In: Miró i Andreu O, Burillo Putze G, Julián Jiménez A, Martín Sánchez FJ, Tomás Vecina S, Mateos Rodríguez A, et al., editors. *Emergencias: Revista Científica de la Sociedad Española de Medicina de Urgencias y Emergencias*. Madrid: Sanidad y Ediciones, S.L. (SANED); 2013 [accessed 17.01.16]. Available from: <https://medicinainternaaldia.files.wordpress.com/2014/07/sindrome-convulsivo.pdf>
  28. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010;51:676–85.
  29. Berg AT, Millichap JJ. The 2010 revised classification of seizures and epilepsy. *Continuum (Minneapolis)*. 2013;19:571–97.
  30. Operational classification of seizure types by the International league against epilepsy. Available from: <http://www.ilae.org/visitors/centre/documents/ClassificationSeizureILAE-2016.pdf> [accessed 16.11.16].
  31. Mercadé Cerdá JM, Toledo Argany M. Urgencias en crisis epilépticas y epilepsia. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012*. 1. Guía oficial de práctica clínica en epilepsia. Madrid: LUZÁN 5, S.A.; 2012. p. 96–107.
  32. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. *Epilepsia*. 2015;56:1515–23.
  33. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline



- Committee of the American Epilepsy Society. *Epilepsy Curr.* 2016;16:48–61.
34. Rosenow F, Knake S. Status epilepticus in adults. *Handb Clin Neurol.* 2012;108:813–9.
  35. Holland K, Shinnar S. Status epilepticus in children. *Handb Clin Neurol.* 2012;108:795–812.
  36. Walker M. Status epilepticus: an evidence based guide. *BMJ.* 2005;331:673–7.
  37. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. *Lancet Neurol.* 2006;5:246–56.
  38. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. *Lancet Neurol.* 2011;10:922–30.
  39. Betjemann JP, Lowenstein DH. Status epilepticus in adults. *Lancet Neurol.* 2015;14:615–24.
  40. Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. *Lancet Neurol.* 2007;6:329–39.
  41. Sutter R, Semmlack S, Kaplan PW. Nonconvulsive status epilepticus in adults—insights into the invisible. *Nat Rev Neurol.* 2016;12:281–93.
  42. Rossetti AO, Trinka E, Stähli C, Novy J. New ILAE versus previous clinical status epilepticus semiologic classification: analysis of a hospital-based cohort. *Epilepsia.* 2016;57:1036–41.
  43. Koutroumanidis M. Comment on the recent ILAE special report on the definition and classification of status epilepticus. *Epilepsia.* 2016;57:1199–200.
  44. Trinka E, Kälviäinen R. 25 years of advances in definition, classification and treatment of status epilepticus. *Seizure.* 2016; pii:S1059-1311(16)30199-6 [Epub ahead of print].
  45. Herranz Fernández JL, Forcadad Berdusán MI. Principios farmacológicos del tratamiento antiepiléptico. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012. 1. Guía oficial de práctica clínica en epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 75–108.
  46. Toledano Delgado R, García Molares I. Modo de empleo de los fármacos antiepilépticos. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012. 1. Guía oficial de práctica clínica en epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 85–90.
  47. Mauri Llerda JA, Suller Martia A, de la Peña Mayor P, Martínez Ferri M, Poza Aldea JJ, Gómez Alonso J, et al. Guía oficial de la Sociedad Española de Neurología de práctica clínica en epilepsia *Epilepsia* en situaciones especiales: comorbilidades, mujer y anciano. *Neurología.* 2015;30:510–7.
  48. Mauri Llerda JA, Tejero Juste C. Tratamiento antiepiléptico agudo y crónico en situaciones especiales. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012. 1. Guía oficial de práctica clínica en epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 136–46.
  49. Asconapé JJ. Epilepsy: new drug targets and neurostimulation. *Neurol Clin.* 2013;31:785–98.
  50. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia.* 2010;51:1069–77.
  51. Mercadé Cerdá JM, Toledo Argani M, Mauri Llerda JA, López González FJ, Salas Puig X, Sancho Rieger J. Guía oficial de la Sociedad Española de Neurología de práctica clínica en epilepsia. *Neurología.* 2016;31:121–9.
  52. Muñoz Carmona DM, Ortega Rodríguez MJ. Manejo práctico de los síntomas neurológicos en urgencias del paciente oncológico. In: Muñoz Carmona DM, Bayo Calero J, editores. *ONCOURG®: Guía Práctica de Actuación en Urgencias Oncológicas para especialistas internos residentes.* Sevilla: D.-M. Muñoz; 2013. p. 49–61.
  53. Camacho Pizarro T, de la Ossa Sendra MJ, Duarte Rodríguez M, Fernández López A, Fernández Romero RI, Luna Cano JJ, et al. Protocolo para el seguimiento del tratamiento farmacológico individualizado en pacientes con sedación paliativa. In: Berenguer García MJ, Gómez Arcas M, editors. *Consejería de Salud y Bienestar Social.* Sevilla: Junta de Andalucía; 2012. p. 1–50.
  54. Rojas-Marcos I, Tortosa Moreno A, Bruna Escuer J. Neoplasias cerebrales. In: Pascual Gómez J, editor. *Tratado de Neurología.* 2.ª ed. Madrid: LUZÁN 5, S.A.; 2012. p. 397–442.
  55. Asensio Asensio M, López-Trigo Pichó FJ. Crisis sintomáticas agudas/crisis asociadas a situaciones específicas. In: Carreño Martínez M, Casas Fernández C, Gil-Nagen Rein A, Salas Puig J, Serratos Fernández JM, Villanueva Haba V, et al., editors. *Tratado de epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 487–502.
  56. Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. *Epilepsia.* 2010;51:671–5.
  57. Corredera García E, Becerra Cuñat JL. Epilepsia postraumática y tumoral. In: Carreño Martínez M, Casas Fernández C, Gil-Nagen Rein A, Salas Puig J, Serratos Fernández JM, Villanueva Haba V, et al., editors. *Tratado de epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 503–18.
  58. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. *Lancet Neurol.* 2003;2:404–9.
  59. Sarin R, Murthy V. Medical decompressive therapy for primary and metastatic intracranial tumours. *Lancet Neurol.* 2003;2:357–65.
  60. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. *Neurol Clin.* 2007;25:1035–71, ix.
  61. Bruna J, Miró J, Velasco R. Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment. *Expert Rev Clin Pharmacol.* 2013;6:333–44.
  62. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. *Neuro Oncol.* 2016;18:779–89.
  63. Nguyen TD, DeAngelis LM. Brain metastases. *Neurol Clin.* 2007;25:1173–92, x-xi.
  64. Pruitt AA. Medical management of patients with brain tumors. *Continuum (Minneapolis).* 2015;21:314–31.
  65. Martínez Gutiérrez R, Vega Alonso E. Urgencias oncológicas. In: Aguilar Rodríguez F, Bisbal Pardo O, Gómez Cuervo C, de Lagarde Sebastián M, Maestro de la Calle G, Pérez-Jacoiste Asín MA, et al., editors. *Manual de diagnóstico y terapéutica médica. Hospital Universitario 12 de Octubre. 7.ª ed.* Madrid: MSD; 2013. p. 1126–41.
  66. Advanced trauma life support. Available from: [https://en.wikipedia.org/wiki/Advanced\\_trauma\\_life\\_support](https://en.wikipedia.org/wiki/Advanced_trauma_life_support) [accessed 17.01.16].
  67. Encina Aguirre Y. Oncológicas. El enfermo oncológico en urgencias. In: Servicio de Urgencias del Hospital de Navarra, editor. *Libro electrónico de Temas de Urgencia* [accessed 17.01.16]. Available from: <http://www.cfnavarra.es/salud/PUBLICACIONES/Libro%20electronico%20de%20temas%20de%20Urgencia/11.Oncologicas/El%20enfermo%20oncologico%20en%20Urgencias.pdf>
  68. Iban Ochoa R, Morejón Huerta B. Urgencias neurológicas. In: Fernández Fernández G., editor. *Guía de urgencias oncológicas.* 2014; p. 31-8 [accessed 17.01.16]. Available from: <https://drive.google.com/file/d/0B7LpU5xHwFp1LVFQT0hwUt3S0k/view>

69. Manejo de síntomas neurológicos. In: Agustín Illueca MP, Arrieta Canales J, Benites Burgos A, del Río García ML, Moral Lamela AI, Rodríguez Franco E, et al., editors. Manual para el manejo del paciente en cuidados paliativos en urgencias extrahospitalarias. Barcelona: Editores 2011-SUMMA 112; 2011. p. 37-40 [accessed 17.01.16]. Available from: <http://www.madrid.org/bvirtual/BVCM017095.pdf>
70. Domínguez-Páez M, Herranz-Fernández JL, Villanueva-Haba V, Sánchez-Álvarez JC, Olivares-Granados G, Sola RG, et al. Control de las crisis epilépticas durante el postoperatorio inmediato de los tumores cerebrales supratentoriales: recomendaciones del Grupo de Neurocirugía Funcional y Estereotáctica de la Sociedad Española de Neurocirugía. Neurocirugía (Astur). 2012;23:29–35.
71. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886–93.
72. Tremont-Lukats IW, Ratalil BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;CD004424.
73. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:97–102.
74. Protocolo de manejo de las crisis comiciales del paciente oncológico. Servicio de Oncología Radioterápica. Madrid: Hospital Universitario Ramón y Cajal; 2015.
75. Thompson D, Takeshita J, Thompson T, Mulligan M. Selecting antiepileptic drugs for symptomatic patients with brain tumors. J Support Oncol. 2006;4:411–6.
76. Cestari DM, Weine DM, Panageas KS, Segal AZ, deAngelis LM. Stroke in patients with cancer: incidence and etiology. Neurology. 2004;62:2025–30.
77. Taillibert S, Delattre JY. Palliative care in patients with brain metastases. Curr Opin Oncol. 2005;17:588–92.
78. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006;20:1337–61.
79. Sizoo EM, Braam L, Postma TJ, Pasman HR, Heimans JJ, Klein M, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol. 2010;12:1162–6.
80. Gofton TE, Graber J, Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neurooncol. 2012;108:527–34.
81. Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011;13:413–26.
82. Shah U, Morrison T. A review of the symptomatic management of malignant gliomas in adults. J Natl Compr Canc Netw. 2013;11:424–9.
83. Walbert T, Khan M. End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol. 2014;117:217–24.
84. Sizoo EM, Koekkoek JA, Postma TJ, Heimans JJ, Pasman HR, Deliens L, et al. Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase. BMJ Support Palliat Care. 2014;4:77–80.
85. Pompili A, Telera S, Villani V, Pace A. Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients. Neurosurg Focus. 2014;37:E5.
86. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015;17:488–504.
87. Walbert T, Chasteen K. Palliative and supportive care for glioma patients. Cancer Treat Res. 2015;163:171–84.
88. Thier K, Calabek B, Tinchon A, Grisold W, Oberndorfer S. The last 10 days of patients with glioblastoma: assessment of clinical signs and symptoms as well as treatment. Am J Hosp Palliat Care. 2016;33:985–8.
89. Koekkoek JA, Postma TJ, Heimans JJ, Reijneveld JC, Taphoorn MJ. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. Support Care Cancer. 2016;24:1633–8.
90. Newton HB. Symptom management and supportive care of the patient with brain metastases. Cancer Treat Res. 2007;136:53–73.
91. Barfi K, Newton H, von Roenn J. Palliative care for patients with brain metastases. Cancer Treat Res. 2007;136:215–33.
92. Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in adults. Am Fam Physician. 2008;77:1423–30.
93. Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. Am Fam Physician. 2016;93:211–7.
94. Daly FN, Schiff D. Supportive management of patients with brain tumors. Expert Rev Neurother. 2007;7:1327–36.
95. Jenkins A. A case of phenytoin toxicity in a patient with advanced lung cancer. Palliat Med. 2006;20:479–80.
96. Bajwah S. Management of phenytoin toxicity in palliative care. Palliat Med. 2007;21:63.
97. Wusthoff CJ, Shellhaas RA, Licht DJ. Management of common neurologic symptoms in pediatric palliative care: seizures, agitation, and spasticity. Pediatr Clin North Am. 2007;54:709–33, xi.
98. Kuhlen M, Hoell J, Balzer S, Borkhardt A, Janssen G. Symptoms and management of pediatric patients with incurable brain tumors in palliative home care. Eur J Paediatr Neurol. 2016;20:261–9.
99. Schrijvers D, van Fraeyenhove F. Emergencies in palliative care. Cancer J. 2010;16:514–20.
100. Pace A, Villani V, di Lorenzo C, Guariglia L, Maschio M, Pompili A, et al. Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neurooncol. 2013;111:83–6.
101. Tradounsky G. Seizures in palliative care. Can Fam Physician. 2013;59:951–5, e401–05.
102. Sizoo EM, Grisold W, Taphoorn MJ. Neurologic aspects of palliative care: the end of life setting. Handb Clin Neurol. 2014;121:1219–25.
103. Fritz L, Dirven L, Reijneveld JC, Koekkoek JA, Stiggelbout AM, Pasman HR, et al. Advance care planning in glioblastoma patients. Cancers (Basel). 2016;8, pii: E102.
104. McDonald MW, McMullen KP. A new paradigm in treatment of brain metastases. Curr Probl Cancer. 2015;39:70–88.
105. Corral Corral I, Quereda Rodríguez-Navarro C. Manifestaciones neurológicas de la infección por el virus de la inmunodeficiencia humana. In: Mateos Marcos V, Porta Etessam J, editors. Meningitis, encefalitis y otras infecciones del SNC. Barcelona: Elsevier España, S.L.; 2014. p. 201–18.
106. Nath A. Neurologic complications of human immunodeficiency virus Infection. Continuum (Minneapolis). 2015;21:1557–76.
107. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51:251–6.
108. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18.
109. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28.
110. Protocolos médicos y manual de primeros auxilios [accessed 17.01.16]. Available from: [https://sedelectronica.gjjon.es/multimedia\\_objects/download?object\\_type=document&object\\_id=112801](https://sedeelectronica.gjjon.es/multimedia_objects/download?object_type=document&object_id=112801)
111. Towne AR, Pellock JM, Ko D, deLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35:27–34.

112. Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. *Epilepsy Res.* 2011;93:1–10.
113. Sutter R, Kaplan PW, Rüegg S. Outcome predictors for status epilepticus—what really counts. *Nat Rev Neurol.* 2013;9:525–34.
114. González-Cuevas M, Toledo-Argany M, Santamarina-Pérez E, Salas-Puig J. Protocolo terapéutico de la crisis epiléptica y del status epiléptico en Urgencias. *Medicine.* 2015;11:4404–8.
115. Haut SR, Lipton RB, leValley AJ, Hall CB, Shinnar S. Identifying seizure clusters in patients with epilepsy. *Neurology.* 2005;65:1313–5.
116. Garcia P. Patients with seizure clusters—identification of a high-risk group. *Epilepsy Curr.* 2009;9:12–3.
117. Towne AR, Waterhouse EJ, Boggs JG, Garnett LK, Brown AJ, Smith JR Jr, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. *Neurology.* 2000;54:340–5.
118. Vega C, Bañon González RM. Epilepsia postraumática, evaluación de los criterios de causalidad. A propósito de un caso. *Trauma Fund MAPFRE.* 2010;21:53–7. Available from: [http://www.mapfre.com/fundacion/html/revistas/trauma/v21n1/pdf/02\\_09.pdf](http://www.mapfre.com/fundacion/html/revistas/trauma/v21n1/pdf/02_09.pdf) [accessed 18.06.16].
119. Tejero J. EEG patológico. Alteración de los patrones EEG. Actividad epileptiforme. In: Tejero J, editor. *Electroencefalografía clínica básica.* Barcelona: Viguera Editores, S.L.; 2005. p. 187–214.
120. Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? *Oncology.* 2005;28:391–6.
121. Lim D, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II study. *J Neurooncol.* 2009;93:349–54.
122. Rosati A, Buttolo L, Steffini R, Todeschini A. Efficacy and safety of levetiracetam in patients with glioma. A clinical prospective study. *Arch Neurol.* 2010;67:343–6.
123. Van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. *J Neurol.* 2009;256:1519–26.
124. Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treatment with levetiracetam monotherapy: preliminary data of an open-label study. *Neurol Sci.* 2009;30:353–9.
125. Lee JW, Bromfield EB, Kesari S. Antiemetic properties of the antiepileptic drug levetiracetam. *N Engl J Med.* 2008;359:1853.
126. Maschio M, Dinapoli L, Vidiri A, Pace A, Fabi A, Pompili A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-relates epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. *J Exp Clin Cancer Res.* 2009;28:60.
127. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. *Can J Neurol Sci.* 1996;23:128–31.
128. Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. *Clin Neurol Neurosurg.* 2009;111:171–3.
129. Striano S, Striano P, Boccella P, Nocerino C, Bilo L. Tiagabine in glial tumors. *Epilepsy Res.* 2002;49:81–5.
130. Maschio M, Dianpoli L, Zarabla A, Pompili A, Carapella CM, Pace A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. *J Neurooncol.* 2008;86:61–70.
131. Maschio M, Dinapoli L, Saveriano F, Pompili A, Carapella CM, Vidiri A, et al. Efficacy and tolerability of zonisamide as add-on in brain tumor relates epilepsy: preliminary report. *Acta Neurol Scand.* 2009;120:210–2.
132. Weller M, Goria T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology.* 2011;77:1156–64.
133. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. *Neuro Oncol.* 2010;12:917–27.
134. Codina Francisco M, Falip Centellas M, Torradadella de Reynoso P. *Guía práctica. Urgencias en epilepsia.* Barcelona: Ediciones Mayo, S.A.; 2003.
135. Lago Pose E, Roca Fernández FJ. Neurología. Crisis comiciales. In: Fdz-Obanza Windscheid E, Pérez Tenreiro M, Calvo López R, Mayán Conesa P, Bembibre Vázquez L, editors. *ABCDE en urgencias extrahospitalarias.* PraxisMédica; 2009. p. 190-5 [accessed 17.01.16]. Available from: <http://www.praxismedica.org>
136. Zaballos F. Crisis comicial y estatus epiléptico. In: Arcos B, Bosch R, del Pozo C, Martínez JL, Sánchez-Carpena J, Sempere G, editors. *Urgencias 2010.* H. U. Dr. Preset, Valencia. Majadahonda: Ergon; 2009. p. 153–4.
137. García Gallego A, Garcés Sánchez M, Gómez Siurana E, Ramírez, Gallego P, Villanueva Haba V. Protocolo sobre el manejo de las crisis epilépticas en urgencias. Valencia: Hospital Universitario La Fe; 2014.
138. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. *N Engl J Med.* 2012;366:591–600.
139. Dulin JD, Noreika DM, Coyne PJ. Management of refractory status epilepticus in an actively dying patient. *J Pain Palliat Care Pharmacother.* 2014;28:243–50.
140. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. *Cochrane Database Syst Rev.* 2008;CD001905.
141. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. *Lancet.* 2005;366:205–10.
142. Brigo F, Nardone R, Tezzon F, Trinka E. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. *Epilepsy Behav.* 2015;49:325–36.
143. European Medicines Agency (EMA). Ficha técnica de midazolam en solución bucal (Buccolam®) [accessed 10.06.16]. Available from: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/002267/WC500112310.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002267/WC500112310.pdf)
144. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. *Neurology.* 2006;67:340–2.
145. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. *Epilepsia.* 2011;52:1292–6.
146. Liu X, Wu Y, Chen Z, Ma M, Su L. A systematic review of randomized controlled trials on the therapeutic effect of intravenous sodium valproate in status epilepticus. *Int J Neurosci.* 2012;122:277–83.
147. Shin HW, Davis R. Review of levetiracetam as a first line treatment in status epilepticus in the adult patients—what do we know so far? *Front Neurol.* 2013;4:111.
148. Trinka E, Höfler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. *CNS Drugs.* 2014;28:623–39.
149. Rémi C, Lorenzl S, Vyhnalek B, Rastorfer K, Feddersen B. Continuous subcutaneous use of levetiracetam: a retrospective

- review of tolerability and clinical effects. *J Pain Palliat Care Pharmacother.* 2014;28:371–7.
150. Wells GH, Mason LD, Foreman E, Chambers J. Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. *Age Ageing.* 2016;45:321–2.
  151. Lowenstein DH, Alldredge BK. Status epilepticus. *N Engl J Med.* 1998;338:970–6.
  152. Kim LG, Johnson TL, Marson AG, Chadwick DW, MRC MESS Study group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. *Lancet Neurol.* 2006;5:317–22.
  153. Cañadillas Hidalgo F, Morales Martínez MD. Fármacos antiepilépticos genéricos. In: Mercadé Cerdá JM, Sancho Rieger J, Mauri Llerda JA, López González FJ, Salas Puig X, editors. *Guías diagnósticas y terapéuticas de la Sociedad Española de Neurología 2012. 1. Guía oficial de práctica clínica en epilepsia.* Madrid: LUZÁN 5, S.A.; 2012. p. 91–5.
  154. European Medicines Agency (EMA). Ficha técnica de perampanel (Fycompa®) [accessed 24.05.16]. Available from: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/002434/WC500130815.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf)
  155. Rohrer A, Brigo F, Höfler J, Kalss G, Neuray C, Dobesberger J, et al. Perampanel for the treatment of primary generalized tonic–clonic seizures in idiopathic generalized epilepsy. *Expert Opin Pharmacother.* 2016;17:1403–11.
  156. European Medicines Agency (EMA). Ficha técnica de brivaracetam (Briviact®) [accessed 17.11.16]. Available from: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/003898/WC500200206.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003898/WC500200206.pdf)
  157. Markham A. Brivaracetam: first global approval. *Drugs.* 2016;76:517–22.
  158. Hoy SM. Brivaracetam: a review in partial-onset (focal) seizures in patients with epilepsy. *CNS Drugs.* 2016;30:761–72.
  159. Retigabine (Trobalt®): risk of acquired vitelliform maculopathy. Available from: [https://assets.digital.cabinet-office.gov.uk/media/572cb12b40f0b60374000004/Trobalt\\_DHCP\\_sent\\_April\\_2016.pdf](https://assets.digital.cabinet-office.gov.uk/media/572cb12b40f0b60374000004/Trobalt_DHCP_sent_April_2016.pdf) [accessed 24.05.16].
  160. Hirsch LJ, laRoche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, et al. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version. *J Clin Neurophysiol.* 2013;30:1–27.